<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acetaminophen (paracetamol) poisoning: Management in adults and children</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acetaminophen (paracetamol) poisoning: Management in adults and children</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Acetaminophen (paracetamol) poisoning: Management in adults and children</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kennon Heard, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard Dart, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert G Hendrickson, MD, FACMT, FAACT</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michele M Burns, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Ganetsky, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 05, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">Acetaminophen</a> poisoning is among the most common causes of medication-related poisoning and death. It may occur following an acute ingestion or through repeated ingestions of supratherapeutic amounts. The management of the acetaminophen-poisoned patient may include stabilization, decontamination, and administration of <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a>, a specific antidote. Indications for acetylcysteine and/or gastrointestinal decontamination depend on the patient's presenting symptoms, time since and duration of exposure, and serum acetaminophen and aminotransferase concentrations. </p><p>The management of <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> poisoning in adults and children is reviewed here and summarized in the table  (<a class="graphic graphic_table graphicRef143517" href="/z/d/graphic/143517.html" rel="external">table 1</a>). The following related content is discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation and diagnosis of <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> poisoning, use of the Revised Rumack-Matthew nomogram, and determination of risk of liver injury (see  <a class="medical medical_review" href="/z/d/html/340.html" rel="external">"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/17161.html" rel="external">"Clinical manifestations and diagnosis of acetaminophen (paracetamol) poisoning in children and adolescents"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation and management of liver injury or failure (see  <a class="medical medical_review" href="/z/d/html/3574.html" rel="external">"Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/3570.html" rel="external">"Acute liver failure in adults: Management and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/16142.html" rel="external">"Acute liver failure in children: Etiology and evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/83172.html" rel="external">"Acute liver failure in children: Management, complications, and outcomes"</a> and  <a class="medical medical_review" href="/z/d/html/3571.html" rel="external">"Drug-induced liver injury"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>General approach to the poisoned patient (see  <a class="medical medical_review" href="/z/d/html/324.html" rel="external">"General approach to drug poisoning in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6496.html" rel="external">"Approach to the child with occult toxic exposure"</a> and  <a class="medical medical_review" href="/z/d/html/13850.html" rel="external">"Initial management of the critically ill adult with an unknown overdose"</a>)</p><p></p><p class="headingAnchor" id="H3957736158"><span class="h1">PATIENT WITH RELIABLE HISTORY AND ACUTE INGESTION</span><span class="headingEndMark"> — </span>An acute ingestion is defined as any pattern of <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> ingestion as long as the serum concentration can be measured within 24 hours of swallowing the first dose [<a href="#rid1">1</a>]. Interpreting acetaminophen concentrations following an acute ingestion is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/340.html" rel="external">"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and evaluation", section on 'Evaluation after acute overdose'</a> and  <a class="medical medical_review" href="/z/d/html/17161.html" rel="external">"Clinical manifestations and diagnosis of acetaminophen (paracetamol) poisoning in children and adolescents", section on 'Laboratory evaluation'</a>.)</p><p class="headingAnchor" id="H2443639738"><span class="h2">Within eight hours of ingestion</span><span class="headingEndMark"> — </span>If the patient can provide a reliable history regarding the time of an acute ingestion and there is no liver injury on presentation, then the risk of developing liver injury needs to be determined as<strong> </strong>early symptoms do not reliably predict or exclude <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> toxicity. Liver injury is defined biochemically by an elevation of the alanine aminotransferase (ALT) or aspartate aminotransferase (AST) concentration. If the aminotransferases are elevated (or above baseline if chronically abnormal), then the patient should receive <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> regardless of the acetaminophen concentration since liver injury would not be expected to develop this rapidly, and thus, the history should be considered unreliable. (See <a class="local">'Patient with unreliable history'</a> below.) </p><p>Serious hepatotoxicity is uncommon and death extremely rare if <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> is administered within eight hours following <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> overdose and before the onset of liver injury [<a href="#rid2">2-4</a>]. (See <a class="local">'Efficacy and mechanism'</a> below.)</p><p>The patient may need supportive care with intravenous (IV) fluids and antiemetics. (See  <a class="medical medical_review" href="/z/d/html/2537.html" rel="external">"Approach to the adult with nausea and vomiting", section on 'Drug therapy'</a>.)</p><p>Rarely, a patient with a high-risk ingestion (typically &gt;30 grams) can develop altered mental status and a metabolic acidosis with hyperlactemia early (typically within eight hours) following ingestion [<a href="#rid5">5</a>]. Management is discussed below. (See <a class="local">'Patient with high-risk ingestion'</a> below.)</p><p class="headingAnchor" id="H910900508"><span class="h3">Within four hours of ingestion</span></p><p class="headingAnchor" id="H1616174007"><span class="h4">Gastrointestinal decontamination</span><span class="headingEndMark"> — </span>In a patient who presents within four hours of a known or suspected potentially toxic (single dose ≥150 mg/kg or 7.5 g) <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> ingestion, we suggest administering a single dose of activated charcoal (AC). The dose is 1 g/kg (maximum dose 50 g) orally. Contraindications to AC administration include gastrointestinal obstruction or altered mental status with an unprotected airway. Tracheal intubation should <strong>not</strong> be performed solely for the purpose of giving AC. (See  <a class="medical medical_review" href="/z/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient", section on 'Activated charcoal'</a>.)</p><p>The traditional recommendation of limiting treatment with AC to one hour after <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> ingestion may overly restrict the benefit of AC as demonstrated in observational studies and a trial of poisoned patients. In patients with acetaminophen ingestion, studies have shown that AC administration within four hours limits acetaminophen absorption, reduces need for <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> treatment, and reduces risk of developing liver injury [<a href="#rid6">6-9</a>]. In a small trial of intentional acetaminophen ingestions, AC decreased mean acetaminophen concentration by 52 percent (but the placebo arm was stopped early for ethical reasons) [<a href="#rid7">7</a>]. In a large observational study, patients who had ingested more than 10 grams of acetaminophen were less likely to develop concentrations above the Revised Rumack-Matthew nomogram treatment line after receiving AC (with and without gastric lavage) as compared with no decontamination (25 versus 41 percent, odds ratio [OR] 0.50, 95% CI 0.33-0.75) [<a href="#rid9">9</a>].</p><p>We recommend that patients with a potentially toxic ingestion of <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> not routinely undergo gastric emptying with either gastric lavage or induced emesis (eg, syrup of ipecac). Although these procedures have been shown to limit the absorption of acetaminophen after simulated overdose and in clinical trials, they are significantly less effective than AC [<a href="#rid7">7,9-13</a>]. In one trial, AC decreased mean serum acetaminophen concentrations by 52 percent as compared with 39 and 41 percent for gastric lavage and syrup of ipecac, respectively [<a href="#rid7">7</a>]. In a large observational study, gastric lavage in addition to AC provided no additional benefit over AC alone in decreasing the number of patients who developed concentrations above the Revised Rumack-Matthew nomogram treatment line after having ingested more than 10 grams of acetaminophen (23 versus 28 percent) [<a href="#rid9">9</a>]. Furthermore, gastric lavage can increase the risk of aspiration in poisoned patients and persistent vomiting from syrup of ipecac may delay administration of oral <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a>. (See  <a class="medical medical_review" href="/z/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient", section on 'Syrup of Ipecac'</a> and  <a class="medical medical_review" href="/z/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient", section on 'Gastric lavage'</a>.)</p><p class="headingAnchor" id="H1169603642"><span class="h4">Obtain four-hour acetaminophen concentration</span><span class="headingEndMark"> — </span>Unless the patient is developing parent-compound toxicity (altered mental status, metabolic acidosis) due to a high-risk ingestion, we obtain a serum <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> concentration four hours after the ingestion or as soon as possible thereafter to decide if <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> is needed. The benefit of acetylcysteine does not appear to be time dependent within the first four hours following ingestion. (See <a class="local">'Administer acetylcysteine if risk of liver injury'</a> below.)</p><p>Serum concentrations drawn before four hours may not represent peak values and have limited utility. Additionally, AC may limit absorption of a potentially toxic ingestion and obviate the need for <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> as determined by the four-hour concentration. The use of concentrations measured between two to four hours is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/340.html" rel="external">"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and evaluation", section on 'Ingestion of immediate-release acetaminophen'</a>.) </p><p class="headingAnchor" id="H886773972"><span class="h3">Four to eight hours after ingestion</span></p><p class="headingAnchor" id="H3434692517"><span class="h4">Administer acetylcysteine if risk of liver injury</span><span class="headingEndMark"> — </span>Poisoning severity (ie, risk of developing liver injury) following an acute ingestion is quantified by plotting a timed serum <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> concentration on the Revised Rumack-Matthew nomogram  (<a class="graphic graphic_figure graphicRef83590" href="/z/d/graphic/83590.html" rel="external">figure 1</a>). (See  <a class="medical medical_review" href="/z/d/html/340.html" rel="external">"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and evaluation", section on 'Ingestion of immediate-release acetaminophen'</a> and  <a class="medical medical_review" href="/z/d/html/17161.html" rel="external">"Clinical manifestations and diagnosis of acetaminophen (paracetamol) poisoning in children and adolescents", section on 'Acetaminophen concentration'</a>.)</p><p>In a patient with a serum <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> concentration that falls above the Revised Rumack-Matthew nomogram treatment line  (<a class="graphic graphic_figure graphicRef83590" href="/z/d/graphic/83590.html" rel="external">figure 1</a>) following an acute ingestion, we recommend <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a>. Details regarding acetylcysteine administration, including route, dose, adverse effects, monitoring, and deciding when to stop, are discussed below. (See <a class="local">'Acetylcysteine administration and monitoring'</a> below.)</p><p>A patient with an ingestion of an extended-release formulation (labeled for use on an eight-hour basis) or a co-ingestion with an anticholinergic agent or opioid may need a repeat <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> concentration to exclude delayed absorption. If any of these concentrations fall above the treatment line  (<a class="graphic graphic_figure graphicRef83590" href="/z/d/graphic/83590.html" rel="external">figure 1</a>), we recommend <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a>. The circumstances and timing of obtaining a repeat concentration are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/340.html" rel="external">"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and evaluation", section on 'Ingestion of extended-release formulation or anticholinergic/opioid co-ingestion'</a> and  <a class="medical medical_review" href="/z/d/html/17161.html" rel="external">"Clinical manifestations and diagnosis of acetaminophen (paracetamol) poisoning in children and adolescents", section on 'Acetaminophen concentration'</a>.) </p><p class="headingAnchor" id="H2063360908"><span class="h4">Role of gastrointestinal decontamination</span><span class="headingEndMark"> — </span>An asymptomatic patient who presents more than four hours after a reported ingestion is unlikely to benefit from AC. In most cases, <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> absorption is complete by four hours after ingestion. </p><p>However, AC may be useful beyond four hours in a patient with a reliable history of a very large ingestion (&gt;30 grams), following an ingestion of an extend-release formulation  (<a class="graphic graphic_table graphicRef79854" href="/z/d/graphic/79854.html" rel="external">table 2</a>), or with co-ingestion of certain agents that slow gut motility and delay absorption (eg, anticholinergic agents, opioids), especially if there is evidence of ongoing absorption such as an increasing <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> concentration [<a href="#rid1">1</a>]. An observational study found that administration of AC to patients who presented more than four hours after acetaminophen ingestion was associated with lower peak ALT concentrations independent of the time of <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> administration [<a href="#rid14">14</a>]. While limited, this study suggests that administration of AC more than four hours after ingestion may be beneficial, although it included a small number of patients and focused on liver enzyme elevation as the primary outcome, which may not be clinically relevant. Thus, the true benefit of AC when administered more than four hours after acetaminophen overdose is uncertain.</p><p class="headingAnchor" id="H99698459"><span class="h2">Beyond eight hours after ingestion</span><span class="headingEndMark"> — </span>In a patient with a suspected acute ingestion of greater than 150 mg/kg (7.5 g total dose regardless of weight) for whom the serum <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> concentration will not be available until more than eight hours from the time of the ingestion, we recommend administering <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> before the serum acetaminophen concentration results. Beyond eight hours following ingestion, the risk of developing liver injury increases as the time to administration of acetylcysteine increases [<a href="#rid3">3</a>]. </p><p>If the concentration results below the Revised Rumack-Matthew nomogram treatment line  (<a class="graphic graphic_figure graphicRef83590" href="/z/d/graphic/83590.html" rel="external">figure 1</a>), the aminotransferases are normal (or at baseline if chronically abnormal), and the patient does not have signs or symptoms of liver injury, the <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> can be stopped, and no further treatment is needed. Otherwise, continue the acetylcysteine until stopping criteria are met. Details regarding acetylcysteine administrations, including route, dose, adverse effects, monitoring, and deciding when to stop, are discussed below. (See <a class="local">'Acetylcysteine administration and monitoring'</a> below.)</p><p class="headingAnchor" id="H1649004521"><span class="h1">PATIENT WITH RELIABLE HISTORY AND REPEATED SUPRATHERAPEUTIC INGESTION</span><span class="headingEndMark"> — </span>Repeated supratherapeutic ingestion is defined as multiple ingestions during a period greater than 24 hours [<a href="#rid1">1</a>]. The Revised Rumack-Matthew nomogram cannot be used for risk stratification. The dose and duration criteria that define a repeated supratherapeutic ingestion and thus warrant obtaining a serum <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> concentration are the following and discussed in detail separately (see  <a class="medical medical_review" href="/z/d/html/340.html" rel="external">"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and evaluation", section on 'Evaluation after repeated supratherapeutic ingestion'</a> and  <a class="medical medical_review" href="/z/d/html/17161.html" rel="external">"Clinical manifestations and diagnosis of acetaminophen (paracetamol) poisoning in children and adolescents", section on 'Repeated supratherapeutic ingestion'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>If ingestion period was 24 to 48 hours – Ingestion of greater than 6 g/day (150 mg/kg/day) of <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If ingestion period &gt;48 hours – Ingestion of greater than 4 g/day (100 mg/kg/day) of <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>.</p><p></p><p>In a patient with a repeated supratherapeutic ingestion (based on the above criteria) and a serum <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> concentration ≥20 mcg/mL (132 micromol/L) or with elevated aminotransferases (unless they are at baseline if chronically abnormal), we recommend <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> [<a href="#rid1">1,15-17</a>]. The acetylcysteine should be continued until stopping criteria are met. Details regarding acetylcysteine administrations, including route, dose, adverse effects, monitoring, and deciding when to stop, are discussed below. (See <a class="local">'Acetylcysteine administration and monitoring'</a> below.)</p><p>A patient with a history of repeated supratherapeutic ingestion of <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> and elevated aminotransferases should be presumed to have acetaminophen-induced liver injury regardless of the measured serum acetaminophen concentration.</p><p class="headingAnchor" id="H2904097555"><span class="h1">PATIENT WITH UNRELIABLE HISTORY</span><span class="headingEndMark"> — </span>An unreliable or inaccurate history refers to being unable to establish the time of ingestion; conflicting statements; or symptoms, signs, or laboratory values inconsistent with the history (eg, elevated aminotransferases within eight hours of ingestion) [<a href="#rid1">1</a>]. Do not use the Revised Rumack-Matthew nomogram for risk stratification in these circumstances. We recommend the following approach: <strong>  </strong></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">Acetaminophen</a><strong> ≤10 mcg/mL (66 micromol/L) and aminotransferases are normal (or at baseline if chronically abnormal)</strong> – We do not administer <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>"Last known time prior to acute ingestion"</strong> – If the history suggests an ingestion over any period in the 24 hours preceding presentation and it is possible to narrow the initial ingestion to a specific time window (eg, patient had been continually observed until 12 hours prior to admission, so the ingestion could not have occurred more than 12 hours ago), it may be possible to construct a worst-case scenario and plot the measured serum concentration using the "last known time prior to ingestion" as the "time of ingestion." <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">Acetylcysteine</a> would be given if the <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> concentration falls above the Revised Rumack-Matthew nomogram treatment line  (<a class="graphic graphic_figure graphicRef83590" href="/z/d/graphic/83590.html" rel="external">figure 1</a>) based on this scenario.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">Acetaminophen</a><strong> &gt;10 mcg/mL (66 micromol/L) or aminotransferases are elevated (unless the elevation is patient's baseline value)</strong> – Given the unknown risks, we suggest a conservative approach of starting treatment with <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a>. This approach maximizes the potential benefit of acetylcysteine. (See <a class="local">'Acetylcysteine administration and monitoring'</a> below.)</p><p></p><p class="bulletIndent1">We administer <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> for 12 hours and then repeat the serum <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> concentration and the aminotransferases. We stop acetylcysteine if the patient fulfills all the stopping criteria discussed below. (See <a class="local">'Duration of treatment (stopping criteria)'</a> below.)</p><p></p><p class="bulletIndent1">If these conditions are <strong>not</strong> met, treatment should be continued until all the conditions are fulfilled. </p><p></p><p class="bulletIndent1">Although other experts treat for the entire 21-hour infusion (checking the serum <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> and aminotransferases near the end of the infusion and providing further <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> if the aminotransferases are elevated or acetaminophen remains detectable), we are not aware of any patients who have experienced a poor outcome using our shortened approach as long as all endpoints are met.</p><p></p><p class="headingAnchor" id="H1279834331"><span class="h1">PATIENT WITH LIVER INJURY (INCLUDING DELAYED PRESENTATION)</span></p><p class="headingAnchor" id="H2891292621"><span class="h2">Administer acetylcysteine regardless of acetaminophen concentration</span><span class="headingEndMark"> — </span>In a patient with symptoms and signs of liver injury (eg, nausea, vomiting, abdominal pain, elevated aminotransferases, jaundice, kidney injury, coagulopathy, hepatic encephalopathy, cerebral edema)  (<a class="graphic graphic_table graphicRef57032" href="/z/d/graphic/57032.html" rel="external">table 3</a>) and a history of <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> ingestion, we recommend <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a>. Do not use the Revised Rumack-Matthew nomogram for risk stratification in these circumstances.<strong> </strong>Details regarding acetylcysteine administrations, including route, dose, adverse effects, monitoring, and deciding when to stop, are discussed below. (See <a class="local">'Acetylcysteine administration and monitoring'</a> below.)</p><p>This situation typically occurs when presentation for care is delayed (ie, 12 to 24 hours) following ingestion. <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">Acetylcysteine</a> therapy is associated with a benefit, even if started more than 24 hours after ingestion or no <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> is still detectable in the serum. For example, in patients with fulminant hepatic failure from acetaminophen, acetylcysteine decreases mortality and need for liver transplantation [<a href="#rid18">18</a>]. (See <a class="local">'Efficacy and mechanism'</a> below.)</p><p>A patient with a delayed presentation and liver injury should be managed in consultation with a regional poison control center or a medical toxicologist. (See <a class="local">'Regional poison control centers'</a> below.)</p><p class="headingAnchor" id="H1255022104"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>We measure the alanine aminotransferase (ALT), aspartate aminotransferase (AST), international normalized ratio (INR), and serum <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> concentration every 12 hours. More frequent testing does not allow enough time to detect clinically meaningful trends. If the patient develops an ALT or AST &gt;1000 international unit/L, coagulopathy (ie, INR &gt;1.5), or encephalopathy, then the serum bicarbonate, glucose, and creatinine should also be measured every 12 hours. The ALT and AST are used to monitor the degree of liver injury, and the other tests are used to determine possible need for liver transplant [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/z/d/html/3570.html" rel="external">"Acute liver failure in adults: Management and prognosis", section on 'Laboratory testing'</a> and  <a class="medical medical_review" href="/z/d/html/83172.html" rel="external">"Acute liver failure in children: Management, complications, and outcomes", section on 'Laboratory monitoring'</a>.)</p><p>Intensive monitoring (eg, intensive care unit [ICU] admission, cardiac monitor) may be indicated based upon the patient's clinical condition, if a significant co-ingestion is known, or other problems arise. A patient with a mild liver injury can often be managed in a non-ICU setting.</p><p class="headingAnchor" id="H3391902182"><span class="h2">Fulminant hepatic failure</span><span class="headingEndMark"> — </span>In a patient who develops fulminant hepatic failure (hepatic failure is differentiated from liver injury by the onset of impaired synthetic function and/or encephalopathy), we suggest <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> be administered intravenously (IV) instead of orally. There are no studies of oral acetylcysteine dosing in hepatic failure. The dosing protocol is the same as the 21-hour regimen (see <a class="local">'21-hour intravenous protocol'</a> below), except the final infusion rate (6.25 mg/kg/hour) is continued until stopping criteria are met or the patient receives a liver transplantation (and the serum <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> concentration is nondetectable) [<a href="#rid7">7,10,18,20</a>].</p><p>In a patient with fulminant hepatic failure and persistently elevated <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> concentrations, hemodialysis may be an option to increase clearance. (See <a class="local">'Role of extracorporeal removal'</a> below.)</p><p>The increased availability of liver transplantation has resulted in significant improvement in survival rates for patients with fulminant hepatic failure from <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> toxicity [<a href="#rid6">6</a>]. Supportive therapies for the management of acute liver failure and its complications (including encephalopathy, coagulopathy, and acute kidney injury) are described elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3570.html" rel="external">"Acute liver failure in adults: Management and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/83172.html" rel="external">"Acute liver failure in children: Management, complications, and outcomes"</a>.)</p><p class="headingAnchor" id="H66312687"><span class="h3">Indications for consultation with liver transplant team</span><span class="headingEndMark"> — </span>We recommend consultation with a liver transplant team in a patient with any of the following despite <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> treatment [<a href="#rid1">1</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Progressive increase in aminotransferases and worsening coagulation abnormalities</p><p class="bulletIndent1"><span class="glyph">●</span>Encephalopathy </p><p class="bulletIndent1"><span class="glyph">●</span>Multisystem failure </p><p></p><p class="headingAnchor" id="H4117313007"><span class="h3">Modified King's College Criteria</span><span class="headingEndMark"> — </span>In patients with fulminant hepatic failure from <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>, the modified King's College Criteria are helpful to determine prognosis and thus which patients should be managed in a center that offers liver transplantation [<a href="#rid21">21</a>]. Recovery is often observed even in patients who have evidence of severe hepatocellular necrosis and synthetic dysfunction, so not all patients with fulminant hepatic failure will require a liver transplant. Notably, the degree of aminotransferase elevation is not part of these criteria, nor is it considered a prognostic factor. The criteria are below and presented in the algorithm  (<a class="graphic graphic_algorithm graphicRef143516" href="/z/d/graphic/143516.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Arterial lactate &gt;3.5 mmol/L after early fluid resuscitation (ie, at least 1 L) <strong>or</strong> </p><p class="bulletIndent1"><span class="glyph">●</span>Arterial lactate &gt;3.0 mmol/L after adequate fluid resuscitation<strong> </strong>(ie, tissue perfusion restored)<strong> or</strong></p><p class="bulletIndent1"><span class="glyph">●</span>Arterial pH &lt;7.3 (irrespective of grade of encephalopathy) <strong>or</strong> </p><p class="bulletIndent1"><span class="glyph">●</span>Grade III or IV encephalopathy with <strong>both</strong> a prothrombin time (PT) greater than 100 seconds and a serum creatinine greater than 3.4 mg/dL (300 micromol/L)</p><p></p><p>The original King's College Criteria  (<a class="graphic graphic_table graphicRef77717" href="/z/d/graphic/77717.html" rel="external">table 4</a>) are discussed elsewhere; they did not include an early serum lactate, which improved upon their predictive accuracy [<a href="#rid21">21,22</a>]. The sensitivity and specificity of the modified King's College Criteria for predicting individuals likely to die without transplantation are 95 and 91 percent, respectively. (See  <a class="medical medical_review" href="/z/d/html/3570.html" rel="external">"Acute liver failure in adults: Management and prognosis", section on 'King's College Criteria'</a>.) </p><p class="headingAnchor" id="H3523346555"><span class="h2">Acute kidney injury</span><span class="headingEndMark"> — </span>In the rare instance when severe <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> poisoning is complicated by acute kidney injury, hemodialysis may be necessary based on standard indications (eg, refractory fluid overload, severe hyperkalemia, severe metabolic acidosis, uremia). (See  <a class="medical medical_review" href="/z/d/html/340.html" rel="external">"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and evaluation", section on 'Acute kidney injury (acute renal failure)'</a> and  <a class="medical medical_review" href="/z/d/html/1927.html" rel="external">"Kidney replacement therapy (dialysis) in acute kidney injury in adults: Indications, timing, and dialysis dose", section on 'Urgent indications'</a>.)</p><p class="headingAnchor" id="H1992669638"><span class="h1">PATIENT WITH IATROGENIC INTRAVENOUS OVERDOSE</span><span class="headingEndMark"> — </span>In a patient who receives a single intravenous (IV) <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> dose ≥90 mg/kg actual total body weight (TBW), receives a cumulative dose ≥150 mg/kg TBW during 24 hours, or has a serum acetaminophen concentration drawn four hours after the infusion was started that falls above the Revised Rumack-Matthew nomogram treatment line  (<a class="graphic graphic_figure graphicRef83590" href="/z/d/graphic/83590.html" rel="external">figure 1</a>), we recommend <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> [<a href="#rid1">1,23</a>]. </p><p>Consultation with a poison control center or medical toxicologist is advised for patients who have received an iatrogenic overdose of IV <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>. (See <a class="local">'Regional poison control centers'</a> below.) </p><p>Most iatrogenic dosing errors have involved a 10-fold overdose in small children caused by calculating the dosage in milligrams but then administering the solution in milliliters [<a href="#rid23">23</a>]. </p><p>The approach to treatment of IV <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> overdose is controversial as clinical experience is limited [<a href="#rid23">23,24</a>]. Some medical toxicologists recommend treatment of all patients who receive an IV dose greater than 60 mg/kg [<a href="#rid24">24</a>]. This conservative position is based on case reports and the concern that IV acetaminophen carries increased risk for hepatotoxicity since it is commonly used in the postoperative and fasting settings, which predispose to depleted glutathione stores [<a href="#rid25">25</a>]. However, we question the conclusions drawn from these case reports and note that IV acetaminophen avoids the first-pass effect and is therefore likely to have less hepatic production of the toxic metabolite n-amino-p-benzoquinoneimine despite a higher peak serum concentration. </p><p class="headingAnchor" id="H1337575789"><span class="h1">PATIENT WITH HIGH-RISK INGESTION</span></p><p class="headingAnchor" id="H3739959010"><span class="h2">Supportive care</span><span class="headingEndMark"> — </span>A patient with a high-risk ingestion (&gt;30 grams) may be critically ill early following the overdose and before hepatic failure develops due to parent-compound toxicity [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/z/d/html/340.html" rel="external">"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and evaluation", section on 'Parent compound toxicity (high-risk ingestion)'</a>.)</p><p>The following supportive measures may be required:</p><p class="bulletIndent1"><span class="glyph">●</span>Airway management for altered mental status (see  <a class="medical medical_review" href="/z/d/html/268.html" rel="external">"The decision to intubate"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Intravenous (IV) fluids and/or vasopressors for shock (see  <a class="medical medical_review" href="/z/d/html/1619.html" rel="external">"Use of vasopressors and inotropes"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Bicarbonate therapy for severe metabolic acidosis (see  <a class="medical medical_review" href="/z/d/html/2294.html" rel="external">"Bicarbonate therapy in lactic acidosis"</a>)</p><p></p><p>We recommend consultation with a poison center or medical toxicologist given the management complexities and risk of developing liver injury despite <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> treatment in these patients. (See <a class="local">'Regional poison control centers'</a> below.)</p><p class="headingAnchor" id="H3137051075"><span class="h2">Gastrointestinal decontamination</span><span class="headingEndMark"> — </span>We administer a single dose of activated charcoal (AC) even if beyond four hours after ingestion, especially if there is evidence of ongoing absorption such as an increasing <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> concentration [<a href="#rid1">1</a>]. Dosing and contraindications are discussed above and separately. (See <a class="local">'Gastrointestinal decontamination'</a> above and  <a class="medical medical_review" href="/z/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient", section on 'Activated charcoal'</a>.)</p><p class="headingAnchor" id="H3528963076"><span class="h2">Administer acetylcysteine early</span><span class="headingEndMark"> — </span>In a patient with a history of high-risk <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> ingestion (&gt;30 grams) or signs of parent-compound toxicity (eg, hemodynamic instability, altered mental status, metabolic acidosis), we administer <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> as rapidly as possible instead of waiting for the serum acetaminophen concentration to result. Dosing is discussed below. (See <a class="local">'High-risk patients'</a> below.) </p><p class="headingAnchor" id="H1064765219"><span class="h2">Role of extracorporeal removal</span><span class="headingEndMark"> — </span>In a patient with a serum <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> concentration ≥900 mcg/mL (5960 micromol/L) and altered mental status or metabolic acidosis, we suggest hemodialysis in addition to <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> [<a href="#rid1">1,26</a>]. These recommendations are based on expert opinion and the observation that hemodialysis can clear acetaminophen and toxic metabolites from serum. Hemodialysis can also correct a metabolic acidosis. However, there are many reported cases of recovery with acetylcysteine therapy alone, and in the authors' experience, hemodialysis is rarely needed even for severe poisoning. </p><p>Dosing of <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> during hemodialysis is discussed below. (See <a class="local">'During hemodialysis'</a> below.)</p><p>The safety and efficacy of <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> generally leaves no role for dialysis in the standard management of <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> poisoning even though acetaminophen is cleared by hemodialysis [<a href="#rid27">27,28</a>]. Hemodialysis is not an alternative to acetylcysteine therapy if acetylcysteine is available. However, hemodialysis should be performed when standard indications are present independent of the poisoning. (See <a class="local">'Acute kidney injury'</a> above and  <a class="medical medical_review" href="/z/d/html/325.html" rel="external">"Enhanced elimination of poisons"</a>.) </p><p class="headingAnchor" id="H4"><span class="h1">ACETYLCYSTEINE ADMINISTRATION AND MONITORING</span></p><p class="headingAnchor" id="H1770741075"><span class="h2">Choice of protocol</span><span class="headingEndMark"> — </span>We agree with an expert consensus statement that whichever regimen is chosen, it should deliver at least 300 mg/kg <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> orally or intravenously (IV) during the first 20 to 24 hours of treatment [<a href="#rid1">1</a>]. Many acetylcysteine protocols have been described, and some debate continues about the appropriate route and duration following acute ingestion. </p><p>The 21-hour IV protocol is used most often, and a 20-hour simplified (two-bag) protocol is a reasonable alternative. An oral dosing protocol is also a reasonable alternative in certain patients, discussed immediately below. </p><p>We administer <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> until stopping criteria are met. We do not adhere to a predefined duration (eg, 21 hours) and do not stop acetylcysteine without reassessing the patient [<a href="#rid1">1</a>]. Shorter (eg, 12-hour) protocols have been described but also rely on stopping criteria and are not solely time based. (See <a class="local">'Duration of treatment (stopping criteria)'</a> below.)</p><p class="headingAnchor" id="H3684293556"><span class="h3">Choice of intravenous versus oral</span><span class="headingEndMark"> — </span>There are no head-to-head trials comparing IV and oral <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> protocols in patients treated early after ingestion. In most patients, either the oral or IV route is acceptable. Available data suggest that both routes are effective and differences are minimal [<a href="#rid29">29,30</a>]. For example, a meta-analysis of observational studies included 5164 patients who received acetylcysteine and found a similar rate of liver injury for the IV and oral routes (13.2 versus 12.6 percent) [<a href="#rid29">29</a>]. IV administration is favored for patients with any of the following: </p><p class="bulletIndent1"><span class="glyph">●</span>Intractable vomiting</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Contraindications to oral administration (eg, aspiration risk due to altered mental status, pancreatitis, bowel ileus or obstruction, bowel injury)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hepatic failure (see <a class="local">'Fulminant hepatic failure'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Refusing oral administration</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy (see <a class="local">'Pregnant patients'</a> below)</p><p></p><p>Nonallergic anaphylactic reactions (NAARs) can occur in 10 to 20 percent of patients treated with IV <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a>, most commonly during the first hour of infusion and almost exclusively within the first five hours [<a href="#rid31">31</a>]. Patients who receive IV acetylcysteine should be closely monitored in a setting where personnel, medications, and equipment necessary to manage anaphylaxis are readily available. (See <a class="local">'Nonallergic anaphylactic reactions to intravenous route'</a> below and <a class="local">'Setting for intravenous acetylcysteine infusion'</a> below.)</p><p class="headingAnchor" id="H6"><span class="h3">21-hour intravenous protocol</span><span class="headingEndMark"> — </span>The 21-hour IV protocol for <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> is approved by the US Food and Drug Administration and has been in use in the United Kingdom since the 1970s. This dosing regimen is complicated and is performed as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Administer an initial loading dose of 150 mg/kg IV over 60 minutes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Next, administer a dose of 50 mg/kg over four hours (ie, infusion at 12.5 mg/kg <strong>per hour</strong> IV for four hours).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Finally, administer a dose of 100 mg/kg over 16 hours (ie, infusion at 6.25 mg/kg <strong>per hour</strong> IV for 16 hours).</p><p></p><p>This treatment protocol provides a total of 300 mg/kg over 21 hours [<a href="#rid32">32</a>]. The treatment period is often extended when patients have large ingestions or elevated serum aminotransferases. (See <a class="local">'Duration of treatment (stopping criteria)'</a> below.)</p><p>In children less than 40 kg, the dose is the same, but the dilution strategy is modified. (See <a class="local">'Intravenous acetylcysteine dilution in children'</a> below.)</p><p class="headingAnchor" id="H2750986197"><span class="h3">Simplified 20-hour (two-bag) intravenous protocol</span><span class="headingEndMark"> — </span>The two-bag regimen simplifies dosing by combing the first two steps of the 21-hour protocol and is given in the following manner:</p><p class="bulletIndent1"><span class="glyph">●</span>First, administer a four-hour infusion at 50 mg/kg per hour IV (ie, total of 200 mg/kg over four hours).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Next, administer a 16-hour infusion at 6.25 mg/kg per hour IV (ie, total of 100 mg/kg over 16 hours).</p><p></p><p>The results of a large retrospective study and experience in Europe, Australia, and the United States indicate that NAARs during treatment with IV <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> can be reduced by using a two-bag regimen instead of the traditional three-bag regimen. In the study, NAARs occurred twice as often in patients treated with the three-bag regimen as compared with the modified two-bag regimen (10 versus 4.3 percent, OR 2.5, 95% CI 1.1-5.8) [<a href="#rid33">33</a>]. Similar studies show comparable results [<a href="#rid34">34-38</a>]. While further trials are needed to confirm the improved safety of the two-bag regimen, we believe it is a reasonable treatment approach in adults and adolescents (ie, patients weighing &gt;40 kg). </p><p class="headingAnchor" id="H3457733301"><span class="h3">Oral protocol</span><span class="headingEndMark"> — </span>The oral <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> protocol consists of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>A loading dose of 140 mg/kg orally, followed by</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A dose of 70 mg/kg orally every four hours until stopping criteria are met (see <a class="local">'Duration of treatment (stopping criteria)'</a> below)</p><p></p><p>The dose does not need to be adjusted if the patient has been treated with activated charcoal (AC). </p><p>The noxious odor and taste of the oral <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> preparation sometimes results in problems with vomiting and inability of patients, especially children, to tolerate multiple doses. (See <a class="local">'Vomiting with oral route'</a> below.)</p><p>A 72-hour <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> oral dosing protocol (time based for total of 18 doses) was used in the United States for more than 30 years with excellent outcomes. The incidence of hepatotoxicity for patients treated within eight hours of ingestion is less than 10 percent but increases to approximately 40 percent if treatment is delayed beyond 16 hours. In the largest study of oral acetylcysteine, no deaths occurred among patients treated before the onset of aminotransferase elevation [<a href="#rid3">3</a>]. Truncated oral protocols have been described, and even though many of these are time based, we treat to the same stopping criteria used for IV administration [<a href="#rid39">39-41</a>]. </p><p>The oral regimen has the theoretical advantage of delivering the antidote directly to the portal circulation. </p><p class="headingAnchor" id="H445740863"><span class="h2">Dosing in special populations</span></p><p class="headingAnchor" id="H30499384"><span class="h3">Weight &gt;100 kg</span><span class="headingEndMark"> — </span>In a patient weighing &gt;100 kg, we provide a maximum <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> dose (either IV or oral) based on a 100 kg weight [<a href="#rid1">1</a>]. The basis for recommending a maximum dose is not clear, but evidence is scant regarding added benefit of acetylcysteine doses calculated with weights above these maximum amounts [<a href="#rid42">42</a>]. However, in a large observational study, clinicians often based dosing on total body weight (TBW) with a low rate of adverse events [<a href="#rid43">43</a>].  </p><p class="headingAnchor" id="H596380508"><span class="h3">High-risk patients</span><span class="headingEndMark"> — </span>We initiate treatment with <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> as rapidly as possible using standard dosing for (see <a class="local">'21-hour intravenous protocol'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span>Patients who present with very high serum <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> concentrations (concentration above the high-risk line on the Revised Rumack-Matthew nomogram)  (<a class="graphic graphic_figure graphicRef83590" href="/z/d/graphic/83590.html" rel="external">figure 1</a>) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a reliable history of high-risk ingestion (&gt;30 g)  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with signs of parent-compound toxicity (altered mental status, metabolic acidosis early following ingestion)</p><p></p><p>Some authors suggest that a higher dose of <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> may be required for high-risk overdoses [<a href="#rid44">44</a>]. Clinicians should contact a poison center or medical toxicologist immediately to determine whether it is appropriate to modify standard treatment. (See <a class="local">'Additional resources'</a> below.)</p><p>If guidance from a poison center or medical toxicologist cannot be obtained and the initial serum <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> concentration is above 300 mcg/mL, a reasonable treatment approach is to double the final infusion rate of the 21-hour IV protocol to 12.5 mg/kg/hour and continue the infusion at this rate until <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> stopping criteria are met. (See <a class="local">'Duration of treatment (stopping criteria)'</a> below.)<strong> </strong></p><p>Several reports have described patients with a high-risk <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> ingestion (&gt;50 g or serum concentration &gt;500 mg/L [3300 micromol/L]) who developed liver injury despite early treatment with IV <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> using the standard 21-hour protocol [<a href="#rid45">45-47</a>]. Several of these cases involved co-ingestion of <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">diphenhydramine</a>, and patients had elevated acetaminophen concentrations at the completion of the 21-hour IV acetylcysteine protocol. The results of a large prospective study and a retrospective study of patients hospitalized for treatment of acute acetaminophen overdose both suggest that a significant number of patients with high-risk ingestion will develop liver injury if treated with standard protocols, even when treatment with acetylcysteine is initiated within eight hours [<a href="#rid5">5,48</a>]. Computerized simulation of overdose supports an increased acetylcysteine dose in this circumstance [<a href="#rid49">49</a>]. However, there are no controlled studies demonstrating that increasing the dose of acetylcysteine prevents liver injury following high-risk overdose.  </p><p class="headingAnchor" id="H3816824951"><span class="h3">During hemodialysis</span><span class="headingEndMark"> — </span>In a patient receiving IV <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a>, we administer a dose of at least 12.5 mg/kg/hour during hemodialysis [<a href="#rid1">1</a>]. We do not adjust the acetylcysteine dose if administered orally during hemodialysis. </p><p>The higher dose is recommended because hemodialysis removes <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> [<a href="#rid50">50,51</a>]. However, it is not clear that the amount of acetylcysteine removed affects clinical outcomes.</p><p class="headingAnchor" id="H9"><span class="h2">Adverse reactions to acetylcysteine</span><span class="headingEndMark"> — </span>While IV <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> administration is prone to dosing errors, significant adverse events stemming from such miscalculations are rare [<a href="#rid52">52</a>]. </p><p class="headingAnchor" id="H10"><span class="h3">Nonallergic anaphylactic reactions to intravenous route</span><span class="headingEndMark"> — </span>Between 10 and 20 percent of patients treated with IV <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> develop a non-IgE mediated NAAR, previously called an anaphylactoid reaction [<a href="#rid15">15,53</a>]. Patients with a prior history of asthma appear to be predisposed. Reactions vary in severity and are tolerable to most patients. Nevertheless, patients receiving IV acetylcysteine warrant close monitoring, and all essential medications and equipment necessary to manage anaphylaxis should be readily available when the initial infusion is administered  (<a class="graphic graphic_table graphicRef58346" href="/z/d/graphic/58346.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef74242" href="/z/d/graphic/74242.html" rel="external">table 6</a>). (See  <a class="medical medical_review" href="/z/d/html/392.html" rel="external">"Anaphylaxis: Emergency treatment"</a>.)</p><p>In a patient who develops an NAAR,<strong> </strong>we suggest the following approach [<a href="#rid54">54</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Flushing without pruritus or urticaria – Stop the <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> infusion for 15 to 30 minutes, then restart at the prior rate unless more severe signs develop. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urticaria – Stop the <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> infusion and administer intramuscular <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a>, <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">diphenhydramine</a>, and a glucocorticoid. The infusion can be restarted at the prior rate once the urticaria resolves.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Angioedema or respiratory symptoms – Stop the <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> infusion and administer <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a>, <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">diphenhydramine</a>, a glucocorticoid, and <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a> (if wheezing). If signs and symptoms resolve, the infusion may be restarted at the prior rate one hour after the administration of epinephrine.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypotension or other persistent systemic anaphylaxis symptoms – Stop the <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> infusion and administer <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a>, <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">diphenhydramine</a>, a glucocorticoid, and <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a> (if wheezing) followed by further anaphylaxis treatment  (<a class="graphic graphic_table graphicRef58346" href="/z/d/graphic/58346.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef74242" href="/z/d/graphic/74242.html" rel="external">table 6</a>). Additional tables demonstrate a method for calculating epinephrine infusion in children with hypotension  (<a class="graphic graphic_table graphicRef56049" href="/z/d/graphic/56049.html" rel="external">table 7</a> and <a class="graphic graphic_table graphicRef66791" href="/z/d/graphic/66791.html" rel="external">table 8</a>). IV acetylcysteine should <strong>not</strong> be restarted. Oral acetylcysteine therapy should be provided as an alternative since these patients will generally not have an NAAR to oral acetylcysteine. If the patient cannot be treated with oral acetylcysteine, or the clinician is considering continuing IV acetylcysteine in patients with anaphylaxis, we encourage consultation with a medical toxicologist or regional poison control center for guidance. (See <a class="local">'Regional poison control centers'</a> below.)</p><p></p><p class="headingAnchor" id="H11"><span class="h3">Vomiting with oral route</span><span class="headingEndMark"> — </span>Approximately 33 percent of patients treated with oral <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> develop nausea and vomiting [<a href="#rid55">55</a>]. The palatability of acetylcysteine can be improved by diluting it to a 5% solution in cola or juice, covering the cup, and drinking through a straw.</p><p>It is reasonable to administer an antiemetic to nauseated patients or patients who have vomited prior to receiving oral <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a>. Serotonin 5-HT3 receptor antagonists (eg, <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a>) are effective antiemetics that are widely used in this setting [<a href="#rid56">56</a>]. </p><p>If a patient vomits within 60 minutes of an oral dose of <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a>, the dose should be repeated. Persistent vomiting in spite of antiemetic therapy is an indication to administer acetylcysteine IV.</p><p class="headingAnchor" id="H1578177117"><span class="h2">Setting for intravenous acetylcysteine infusion</span><span class="headingEndMark"> — </span>The initial infusion of IV <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> should be administered in a setting where oxygen, antihistamine medication (eg, <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">diphenhydramine</a> and <a class="drug drug_general" data-topicid="8436" href="/z/d/drug information/8436.html" rel="external">famotidine</a>), <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a>, <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a>, a glucocorticoid (eg, <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a>), a resuscitation cart, and appropriately-sized airway management equipment is readily available. This is typically the emergency department or critical care setting.</p><p>A patient who tolerates the initial infusion without developing an NAAR does not require critical care monitoring for the remaining doses (but may require monitoring for other conditions). A patient who develops anaphylaxis during <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> infusion and is able to continue the infusion (as discussed above) should be monitored in a critical care setting for the remainder of the entire infusion.</p><p>A patient without liver injury or with minimal liver injury who is tolerating <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> can typically be managed in a non-critical care setting.</p><p class="headingAnchor" id="H3598201508"><span class="h2">Early international normalized ratio elevation</span><span class="headingEndMark"> — </span>INR elevation within the first 20 hours following exposure does not reflect developing synthetic dysfunction or fulminant hepatic failure and does not carry prognostic value. Both therapeutic <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> serum concentrations and high concentrations of <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> can elevate the INR. These elevations are usually mild (INR not greater than 1.7), occur between 4 and 20 hours after ingestion, and resolve as treatment is continued [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H4253668824"><span class="h2">Duration of treatment (stopping criteria)</span><span class="headingEndMark"> — </span>We use clinical endpoints rather than a predetermined time to determine duration of <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> treatment [<a href="#rid1">1,45,47,58,59</a>]. We stop acetylcysteine treatment after a minimum of 300 mg/kg over 20 to 24 hours has been administered and <strong>all</strong> of the following criteria are met [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Serum <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> concentration &lt;10 mcg/mL (66 micromol/L)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>INR &lt;2.0</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ALT and AST are normal (or at baseline if chronically abnormal) or, if elevated, these have decreased 25 to 50 percent from the peak</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patient is clinically well (eg, no nausea/vomiting, no abdominal pain)</p><p></p><p>If all of these criteria are not met, we continue <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> at a rate of at least 6.25 mg/kg/hour (or 70 mg/kg every four hours orally). After 12 hours, we re-evaluate the patient and repeat the ALT, AST, INR, and <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> concentration to see if these stopping criteria are met.</p><p>While the efficacy of IV and oral administration is similar, controversy persists about the optimal duration of <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> therapy, and various approaches to determine duration of therapy have been described [<a href="#rid60">60-62</a>]. The current treatment protocols approved by the US Food and Drug Administration are time based (21 and 72 hours). While these protocols are adequate for the vast majority of patients, it is clear that the 72-hour protocol is longer than needed for most patients while the 21-hour protocol is not long enough for others. There are case reports of patients with toxic <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> concentrations or liver injury at the end of the 21-hour treatment period [<a href="#rid45">45,47,58</a>]. Therefore, we prefer to check laboratory studies prior to stopping treatment.  </p><p>Shorter protocols have been described, but these are essentially tailored to the individual patient and not time based. For example, the Scottish and Newcastle Antiemetic Pretreatment for Paracetamol Poisoning (SNAP) protocol has been adopted into routine practice in various hospitals in the United Kingdom. The SNAP protocol provides a total 300 mg/kg <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> dose but over 12 hours (acetylcysteine IV loading dose of 50 mg/kg per hour for two hours followed by an infusion of 20 mg/kg per hour for 10 hours). However, the infusion is continued if stopping criteria are not met (these criteria are slightly different than described above). Trial and observational data suggest that, compared with the standard 21-hour IV protocol, the SNAP protocol is associated with similar rates of liver injury and fewer adverse effects [<a href="#rid34">34,63</a>]. </p><p class="headingAnchor" id="H3081241703"><span class="h2">Efficacy and mechanism</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">Acetylcysteine</a> is the accepted antidote for <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> poisoning. Acetylcysteine is most effective at preventing liver injury if started within eight hours of an acute ingestion; however, acetylcysteine provides benefit at any time after ingestion, even if there is no acetaminophen still present in serum. </p><p>There are no trials comparing <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> versus supportive treatment alone. However, large cohort studies have shown that, when compared with historical control patients who received supportive care alone, administration of acetylcysteine within 8 to 10 hours of <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> overdose has been associated with a significant reduction in hepatotoxicity (1.6 versus 58.0 percent) and mortality (0.7 versus greater than 5.0 percent) [<a href="#rid3">3,4,64,65</a>]. Multiple studies have confirmed an extremely low incidence of hepatotoxicity following early acetylcysteine administration [<a href="#rid2">2,32,66,67</a>]. Furthermore, in patients with evidence of fulminant hepatic failure following acetaminophen ingestion, even when acetylcysteine was administered late (ie, more than 24 hours), there was decreased development of cerebral edema, improved hepatic function, and decreased mortality [<a href="#rid18">18,68,69</a>].</p><p>No deaths have been reported in any of the large studies of <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> overdose provided <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> was given within 10 hours of ingestion, regardless of the initial serum acetaminophen concentration [<a href="#rid2">2,3,70</a>]. When fulminant hepatic failure and death occur from acetaminophen poisoning, they typically result from delays in seeking medical attention, recognition of poisoning, or institution of appropriate therapy.</p><p>Although some controversy persists regarding mechanism, most toxicologists believe <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> prevents acetaminophen-induced liver injury by restoring hepatic glutathione stores, which are depleted by <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> metabolism to its toxic metabolite n-amino-p-benzoquinoneimine (NAPQI). Sufficient hepatic glutathione stores protect from liver injury by conjugating with NAPQI  (<a class="graphic graphic_figure graphicRef68213" href="/z/d/graphic/68213.html" rel="external">figure 2</a>). Other purported benefits include improved hepatic microcirculatory function and oxygen utilization, scavenging of free radicals, and decreased cerebral edema, especially in patients with acetaminophen-induced liver injury [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H71550036"><span class="h1">INVESTIGATIONAL</span></p><p class="headingAnchor" id="H1828863216"><span class="h2">Biomarkers</span><span class="headingEndMark"> — </span>Biomarkers for early identification of patients at greatest risk for acute liver injury following <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> overdose are being developed and studied [<a href="#rid71">71-74</a>]. Further study of such approaches is needed before any can be recommended for clinical use.</p><p class="headingAnchor" id="H3760767318"><span class="h2">Fomepizole</span><span class="headingEndMark"> — </span>We recommend against routine use of <a class="drug drug_general" data-topicid="8633" href="/z/d/drug information/8633.html" rel="external">fomepizole</a> as an adjunct for treatment of <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> poisoning in the absence of clear evidence of efficacy. However, preliminary evidence suggests that fomepizole may have a role as an adjunct to <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> in patients at high risk for hepatic failure following acetaminophen poisoning. For example, animal studies report that early administration of fomepizole prevents acetaminophen oxidation and limits liver injury [<a href="#rid75">75-77</a>]. Fomepizole may also inhibit Jun-N-terminal kinase (JNK), an important enzyme involved in hepatotoxicity [<a href="#rid78">78</a>]. A human volunteer study demonstrated decreased formation of oxidative metabolites following administration of fomepizole after supratherapeutic doses of acetaminophen [<a href="#rid79">79</a>]. Several case reports have described patients at high risk for significant toxicity who did well following treatment with fomepizole and acetylcysteine [<a href="#rid80">80-82</a>].</p><p><a class="drug drug_general" data-topicid="8633" href="/z/d/drug information/8633.html" rel="external">Fomepizole</a> is approved by the US Food and Drug Administration for the treatment of toxic alcohol poisoning (ie, methanol and ethylene glycol) [<a href="#rid83">83</a>]. It is a potent inhibitor of alcohol dehydrogenase and CYP2E1 and has an excellent safety profile in this setting. </p><p class="headingAnchor" id="H823937139"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H22682529"><span class="h2">Pregnant patients</span><span class="headingEndMark"> — </span>The essential elements of treating <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> overdose do not differ significantly in the pregnant patient. [<a href="#rid84">84,85</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intravenous (IV) </strong><strong>acetylcysteine</strong><strong> preferred over oral formulation</strong> – Many toxicologists prefer to give IV <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> to pregnant patients to reduce the risk of vomiting and ensure more rapid delivery to the fetus. Systemic acetylcysteine concentrations are higher with IV administration, and this may increase the amount of acetylcysteine that crosses the placenta. Nonetheless, both IV and oral routes have been used successfully to treat pregnant patients with <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> overdose, and oral formulations may be used when IV acetylcysteine is not available. Data do not exist to demonstrate that the oral route is less effective in the pregnant patient [<a href="#rid1">1</a>]. Oral administration produces therapeutic acetylcysteine concentrations in cord blood [<a href="#rid86">86</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acetylcysteine</strong><strong> dosing, duration, and monitoring – </strong><a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">Acetylcysteine</a> dosing and the duration of treatment do not differ in the pregnant patient. Standard laboratory studies and monitoring should be performed in pregnant patients with <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> overdose. The need for fetal monitoring is determined by standard clinical criteria. (See  <a class="medical medical_review" href="/z/d/html/340.html" rel="external">"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and evaluation", section on 'General approach and laboratory evaluation'</a> and  <a class="medical medical_review" href="/z/d/html/457.html" rel="external">"Overview of antepartum fetal assessment"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of adverse fetal outcomes</strong> – The most important intervention to prevent pregnancy loss is early treatment with <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a>. In a prospective observational study of 60 pregnant patients with <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> overdose, increasing time to acetylcysteine administration was associated with an increased risk of miscarriage and fetal death [<a href="#rid84">84</a>]. Multiple case reports describe similar findings [<a href="#rid86">86-88</a>]. </p><p></p><p class="bulletIndent1">Since <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> crosses the placenta, maternal overdose causes fetal exposure, and case reports have described fetal and neonatal death from liver necrosis [<a href="#rid84">84,89</a>]. While there are several reports of good outcomes among mothers with liver injury following acetaminophen overdose [<a href="#rid90">90-92</a>], it is likely that maternal toxicity increases the risk for adverse pregnancy outcomes. The rate of fetal malformations does not appear to be increased following acetaminophen overdose, but data are limited [<a href="#rid85">85,93</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maternal risk assessment for liver injury – </strong>The Revised Rumack-Matthew nomogram is used to determine the need for treatment in acute ingestions in pregnant patients as there are no studies suggesting that the risk of maternal hepatotoxicity from <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> overdose is altered by pregnancy [<a href="#rid66">66</a>]. Use of the Revised Rumack-Matthew nomogram is described separately. (See  <a class="medical medical_review" href="/z/d/html/340.html" rel="external">"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and evaluation", section on 'Evaluation after acute overdose'</a>.)</p><p></p><p class="bulletIndent1">In pregnant patients with repeat or chronic ingestions, serum <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> and aminotransferase concentrations should be measured. Treatment with <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> is indicated if the serum acetaminophen concentration is greater than 20 mcg/mL or a serum aminotransferase concentration is elevated (&gt;50 international units/L) [<a href="#rid94">94</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Newborn toxicity</strong> – There are rare case reports of patients delivering while poisoned with <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>. In several of these cases, the neonate also had toxic acetaminophen concentrations [<a href="#rid87">87,95</a>]. In such circumstances, the neonate should be treated with <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> using standard dosing. (See <a class="local">'Intravenous acetylcysteine dilution in children'</a> below and <a class="local">'Acetylcysteine administration and monitoring'</a> above.)</p><p></p><p class="headingAnchor" id="H993535835"><span class="h2">Children</span><span class="headingEndMark"> — </span>The use of <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> among children increased when concerns were raised about an association between <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and Reye syndrome. Small children are particularly vulnerable to iatrogenic dosing errors, especially with IV formulations. Repeated supratherapeutic acetaminophen doses can cause hepatotoxicity in children with risk factors such as decreased oral intake [<a href="#rid96">96-98</a>]. (See  <a class="medical medical_review" href="/z/d/html/5989.html" rel="external">"Fever in infants and children: Pathophysiology and management", section on 'Combining or alternating therapy'</a> and <a class="local">'Patient with Iatrogenic intravenous overdose'</a> above.)</p><p class="headingAnchor" id="H1446737986"><span class="h3">Exploratory ingestions in young children</span><span class="headingEndMark"> — </span>Liver injury is rare among exploratory ingestions (ie, as a result of exploratory behavior) since they usually involve small amounts of <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> in an otherwise asymptomatic child. Approach to treatment consists of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Administer activated charcoal (AC) to a child who presents within four hours of exposure and has ingested a potentially toxic dose (&gt;150 mg/kg); we advise not administering charcoal if the ingested dose is unknown because the vast majority of such ingestions will <strong>not</strong> be significant. (See  <a class="medical medical_review" href="/z/d/html/17161.html" rel="external">"Clinical manifestations and diagnosis of acetaminophen (paracetamol) poisoning in children and adolescents", section on 'Toxic dose'</a> and <a class="local">'Gastrointestinal decontamination'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Plot a timed serum <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> concentration obtained a minimum of four hours after ingestion on the Revised Rumack-Matthew nomogram  (<a class="graphic graphic_figure graphicRef83590" href="/z/d/graphic/83590.html" rel="external">figure 1</a>). (See  <a class="medical medical_review" href="/z/d/html/17161.html" rel="external">"Clinical manifestations and diagnosis of acetaminophen (paracetamol) poisoning in children and adolescents", section on 'Acetaminophen concentration'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Administer <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> to a child with an <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> concentration that is above the treatment line on the Revised Rumack-Matthew nomogram. </p><p></p><p class="headingAnchor" id="H3634194284"><span class="h3">Inappropriate therapeutic dosing</span><span class="headingEndMark"> — </span>Our approach is to children with inappropriate therapeutic dosing is similar to management of adults and is based on whether the history of dose and time of ingestion are reliable and the results of the initial evaluation (including serum <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> concentration and aminotransferases) [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unreliable history of duration of exposure or dose ingested</strong> – Management is based on the serum <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> concentration and the aminotransferases. (See <a class="local">'Patient with unreliable history'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reliable history of duration and dose</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Exposure has occurred during &lt;24 hours and the serum concentration can be measured within 24 hours of swallowing the first dose</strong> – Management is similar to an acute ingestion, and the Revised Rumack-Matthew nomogram is used to determine risk of liver injury. (See <a class="local">'Patient with reliable history and acute ingestion'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dosing has occurred over a period &gt;24 hours</strong> – Management is based on the daily dose ingested, the serum <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> concentration, and the aminotransferases. (See <a class="local">'Patient with reliable history and repeated supratherapeutic ingestion'</a> above.)</p><p></p><p>Significant hepatotoxicity and mortality have been described in children receiving inappropriately high doses of <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> (&gt;90 mg/kg per day) for more than one day. The dose and duration criteria that raise concern for developing liver injury are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/17161.html" rel="external">"Clinical manifestations and diagnosis of acetaminophen (paracetamol) poisoning in children and adolescents", section on 'Repeated supratherapeutic ingestion'</a>.) </p><p>In general, children with no liver injury and no unmetabolized <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> measured in serum may be discharged home [<a href="#rid96">96</a>]. Their caregivers should receive instruction to avoid acetaminophen for the remainder of the current illness. The caregivers also may benefit from education regarding future prevention of such exposures. (See <a class="local">'Prevention of recurrent ingestion'</a> below.)</p><p>Children with a history of multiple supratherapeutic doses of <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> that is associated with liver injury with or without unmetabolized acetaminophen should receive <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> and supportive care in the hospital. We use the same end-points of acetylcysteine therapy as in adults, although the optimal mode of delivery and the duration of therapy in this setting have not been established in trials [<a href="#rid1">1,96,99</a>]. Consultation with a regional poison control center or medical toxicologist is advised. (See <a class="local">'Duration of treatment (stopping criteria)'</a> above and <a class="local">'Regional poison control centers'</a> below.)</p><p>Diagnosing chronic <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> toxicity (ie, repeated excessive dosing over a period &gt;24 hours) is often difficult in children and requires the combination of astute history-taking and recognition of typical clinical and laboratory abnormalities. Signs and symptoms are insidious in onset, often nonspecific (eg, nausea, vomiting, abdominal pain), and easily confused with alternative diagnoses (eg, viral syndrome). Serum concentrations of acetaminophen in this setting do not correlate with toxicity, and the Revised Rumack-Matthew nomogram should <strong>not</strong> be used. Establishing the diagnosis of chronic acetaminophen poisoning frequently involves exclusion of other causes of clinical hepatitis. (See  <a class="medical medical_review" href="/z/d/html/17161.html" rel="external">"Clinical manifestations and diagnosis of acetaminophen (paracetamol) poisoning in children and adolescents", section on 'Repeated supratherapeutic ingestion'</a> and  <a class="medical medical_review" href="/z/d/html/17161.html" rel="external">"Clinical manifestations and diagnosis of acetaminophen (paracetamol) poisoning in children and adolescents", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H248473895"><span class="h3">Intravenous acetylcysteine dilution in children</span><span class="headingEndMark"> — </span>We follow the manufacturer's weight-based dilution protocol for children who weigh less than 40 kg to prevent fluid overload and administering excess free water, which has resulted in hyponatremia, seizures, and death.</p><p class="bulletIndent1">Patients ≤20 kg:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Loading dose: 150 mg/kg in 3 mL per kg of diluent given IV over 60 minutes</p><p class="bulletIndent1"><span class="glyph">●</span>Second dose: 50 mg/kg in 7 mL per kg of diluent given IV over four hours (12.5 mg/kg <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> per hour)</p><p class="bulletIndent1"><span class="glyph">●</span>Third dose: 100 mg/kg in 14 mL per kg of diluent given IV over 16 hours (6.25 mg/kg <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> per hour)</p><p></p><p class="bulletIndent1">Patients &gt;20 and &lt;40 kg:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Loading dose: 150 mg/kg in 100 mL of diluent given IV over 60 minutes</p><p class="bulletIndent1"><span class="glyph">●</span>Second dose: 50 mg/kg in 250 mL of diluent given IV over four hours (12.5 mg/kg <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> per hour)</p><p class="bulletIndent1"><span class="glyph">●</span>Third dose: 100 mg/kg in 500 mL of diluent given IV over 16 hours (6.25 mg/kg <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> per hour)</p><p></p><p class="headingAnchor" id="H1705518113"><span class="h3">Fulminant hepatic failure and liver transplantation</span><span class="headingEndMark"> — </span>In a child with hepatic failure from <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>, the indications for consultation with a liver transplant team are the same as for adults [<a href="#rid1">1</a>]. (See <a class="local">'Indications for consultation with liver transplant team'</a> above.)</p><p>In a young child, even subtle changes in mentation (not clearly explained by another condition) should prompt consultation with a liver transplantation team [<a href="#rid100">100</a>]. Differentiating grade II and III hepatic encephalopathy in a young child can be difficult  (<a class="graphic graphic_table graphicRef83748" href="/z/d/graphic/83748.html" rel="external">table 9</a>), disease progression may be rapid, and grade III or IV encephalopathy carries an extremely poor prognosis. (See  <a class="medical medical_review" href="/z/d/html/16142.html" rel="external">"Acute liver failure in children: Etiology and evaluation", section on 'Physical examination'</a>.)</p><p>Other markers, such as acute kidney injury or progressive increase in the INR, require close monitoring as they may be early signs of impending hepatic failure. A retrospective review included 51 children with <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> overdose and found that children had the same clinical and biochemical risk factors for poor outcomes as adults, although the serum creatinine threshold for poor prognosis was lower for children (&gt;200 micromol/L [2.3 mg/dL] versus &gt;300 micromol/L [3.4 mg/dL] for adults) [<a href="#rid100">100</a>]. Similar to adults, the degree of transaminase elevation is not considered a prognostic factor.</p><p>In a child with progressive hepatic failure from <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>, liver transplantation should be considered as it interrupts the natural course and may be lifesaving  (<a class="graphic graphic_figure graphicRef83763" href="/z/d/graphic/83763.html" rel="external">figure 3</a>). The increased availability of liver transplantation has resulted in significant improvement in survival rates for adolescent and adult patients with fulminant hepatic failure as the result of acetaminophen intoxication [<a href="#rid6">6</a>]. However, liver transplantation is rarely required in children with acetaminophen poisoning and is much less commonly employed compared with adults; thus, experience with outcomes in younger patients is limited. (See  <a class="medical medical_review" href="/z/d/html/83172.html" rel="external">"Acute liver failure in children: Management, complications, and outcomes", section on 'Liver transplant'</a>.)</p><p class="headingAnchor" id="H969948145"><span class="h1">WHEN CAN PATIENT RESUME TAKING ACETAMINOPHEN?</span><span class="headingEndMark"> — </span>After an <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> overdose, patients may safely resume acetaminophen therapy if all of the following conditions are met [<a href="#rid23">23</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>No clinical symptoms</p><p class="bulletIndent1"><span class="glyph">●</span>Serum <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> level &lt;10 mg/L (66 micromol/L)</p><p class="bulletIndent1"><span class="glyph">●</span>Normal serum alanine aminotransferase (ALT)</p><p class="bulletIndent1"><span class="glyph">●</span>Normal prothrombin time (PT) and international normalized ratio (INR)</p><p></p><p class="headingAnchor" id="H41480783"><span class="h1">PREVENTION OF RECURRENT INGESTION</span><span class="headingEndMark"> — </span>In the setting of accidental <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> ingestion, prevention of recurrence involves education of patients, parents, and caregivers regarding the safe and judicious use of acetaminophen and other antipyretics.</p><p>Depending on the circumstance that resulted in ingestion or toxicity, explicit instructions should be given regarding the following [<a href="#rid101">101,102</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Strictly adhering to the weight-based dosing schedules on the label, with a maximum daily dose of 4 grams in adults and 75 mg/kg in children [<a href="#rid103">103</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoiding concurrent administration of <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> with acetaminophen-containing over-the-counter medications or combination acetaminophen-opioid medications.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Caution when administering multiple doses of <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> to a child who has had decreased oral intake.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Caution when using rectal suppositories of <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> because the absorption characteristics and peak concentration times vary depending upon the preparation [<a href="#rid104">104-106</a>]; in addition, suppository preparations should not be divided since it is impossible to know with certainty the dose in each portion [<a href="#rid107">107</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoidance of adult <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> preparations (325 mg and 500 mg) in young children  (<a class="graphic graphic_table graphicRef79854" href="/z/d/graphic/79854.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Storing medications out of the reach of children to prevent exploratory <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> ingestions. (See  <a class="medical medical_review" href="/z/d/html/2873.html" rel="external">"Prevention of poisoning in children"</a>.)</p><p></p><p class="headingAnchor" id="H19"><span class="h1">ADDITIONAL RESOURCES</span></p><p class="headingAnchor" id="H1678316419"><span class="h2">Regional poison control centers</span><span class="headingEndMark"> — </span>Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/138307.html" rel="external">"Society guideline links: Regional poison control centers"</a>.)</p><p class="headingAnchor" id="H2478171507"><span class="h2">Society guideline links</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112689.html" rel="external">"Society guideline links: General measures for acute poisoning treatment"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/114014.html" rel="external">"Society guideline links: Treatment of acute poisoning caused by specific agents other than drugs of abuse"</a>.)</p><p class="headingAnchor" id="H1231822"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/17049.html" rel="external">"Patient education: Acetaminophen poisoning (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H20"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluating risk for liver injury</strong> – The risk of developing liver injury following an acute ingestion (ie, any pattern of <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> ingestion as long as the serum concentration can be measured within 24 hours of swallowing the first dose) is determined by plotting a timed serum acetaminophen concentration on the Revised Rumack-Matthew nomogram  (<a class="graphic graphic_figure graphicRef83590" href="/z/d/graphic/83590.html" rel="external">figure 1</a>). (See <a class="local">'Patient with reliable history and acute ingestion'</a> above.)</p><p></p><p class="bulletIndent1">The Revised Rumack-Matthew nomogram cannot be applied to a patient with an unreliable history or a repeated supratherapeutic ingestion (ie, multiple ingestions during a period greater than 24 hours). (See <a class="local">'Patient with reliable history and repeated supratherapeutic ingestion'</a> above and <a class="local">'Patient with unreliable history'</a> above.)</p><p></p><p class="bulletIndent1">A table is provided that summarizes the management  (<a class="graphic graphic_table graphicRef143517" href="/z/d/graphic/143517.html" rel="external">table 1</a>). The evaluation of <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> poisoning, use of the Revised Rumack-Matthew nomogram, and determination of risk of liver injury are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/340.html" rel="external">"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/17161.html" rel="external">"Clinical manifestations and diagnosis of acetaminophen (paracetamol) poisoning in children and adolescents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal decontamination</strong> – In a patient who presents within four hours of a potentially toxic ingestion of <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> (single dose ≥150 mg/kg or 7.5 g), we suggest administering activated charcoal (AC) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). The dose is 1 g/kg (maximum dose 50 g) orally. Contraindications to charcoal include gastrointestinal obstruction or altered mental status with an unprotected airway; tracheal intubation should <strong>not</strong> be performed solely for the purpose of giving AC. (See <a class="local">'Gastrointestinal decontamination'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antidote (</strong><strong>acetylcysteine</strong><strong>)</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Indications</strong> – In a patient with <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> poisoning at risk for hepatotoxicity (concentration above treatment line on Revised Rumack-Matthew nomogram  (<a class="graphic graphic_figure graphicRef83590" href="/z/d/graphic/83590.html" rel="external">figure 1</a>)) and in a patient with liver injury with exposure to acetaminophen, we recommend treatment with <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). Acetylcysteine is most effective at preventing liver injury if started within eight hours of an acute ingestion but can still decrease need for liver transplant and mortality even in the presence of liver injury without detectable acetaminophen in serum. Patients who should receive acetylcysteine include the following:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Acute ingestion with serum <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> concentration drawn at four hours or more that is above the treatment line on the Revised Rumack-Matthew nomogram  (<a class="graphic graphic_figure graphicRef83590" href="/z/d/graphic/83590.html" rel="external">figure 1</a>). (See <a class="local">'Within eight hours of ingestion'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Suspected single ingestion of greater than 150 mg/kg (7.5 g total dose regardless of weight) when the serum <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> concentration will not be available until more than eight hours from the time of the ingestion. (See <a class="local">'Beyond eight hours after ingestion'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Reliable history with repeated supratherapeutic ingestion and a serum <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> concentration ≥20 mcg/mL (132 micromol/L) or aminotransferases are elevated (unless the elevation is patient's baseline value). (See <a class="local">'Patient with reliable history and repeated supratherapeutic ingestion'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Unreliable history and <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> &gt;10 mcg/mL (66 micromol/L) or aminotransferases are elevated (unless the elevation is patient's baseline value). (See <a class="local">'Patient with unreliable history'</a> above.)<strong> </strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>History of <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> ingestion and <strong>any</strong> evidence of liver injury. (See <a class="local">'Patient with liver injury (including delayed presentation)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dosing protocols</strong> – <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">Acetylcysteine</a> may be given intravenously (IV) or orally. IV administration is preferable in patients with vomiting, nonfunctioning bowel, or pregnancy; those refusing oral administration; and those who present with liver injury. (See <a class="local">'Choice of intravenous versus oral'</a> above.) </p><p></p><p class="bulletIndent2">The most used <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> dosing protocols are the 21-hour IV protocol, the 20-hour "two-bag" IV protocol, and the oral protocol. Whichever protocol is chosen, it should deliver at least 300 mg/kg acetylcysteine during the first 20 to 24 hours of treatment. (See <a class="local">'Choice of protocol'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Duration (stopping criteria) - </strong>We use clinical endpoints rather than time to determine the duration of <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> therapy. We stop acetylcysteine treatment after a minimum of 300 mg/kg over 20 to 24 hours has been administered and <strong>all</strong> of the following criteria are met (see <a class="local">'Duration of treatment (stopping criteria)'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Serum <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> concentration &lt;10 mcg/mL (66 micromol/L)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>International normalized ratio (INR) &lt;2.0</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are normal (or at baseline if chronically abnormal) or, if elevated, these have decreased 25 to 50 percent from the peak</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patient is clinically well (eg, no nausea/vomiting, no abdominal pain)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adverse reactions - </strong>Between 10 and 20 percent of patients treated with IV <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> develop a nonallergic anaphylactic reaction (NAAR). In patients who develop only flushing, stop the acetylcysteine infusion for 15 to 30 minutes, then restart at the prior rate unless more severe signs develop. Management of more severe reactions includes administering intramuscular <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a>, <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">diphenhydramine</a>, and a glucocorticoid. (See <a class="local">'Nonallergic anaphylactic reactions to intravenous route'</a> above and <a class="local">'Vomiting with oral route'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fulminant hepatic failure</strong> – In patients who develop fulminant hepatic failure (differentiated from liver injury by the onset of impaired synthetic function and/or encephalopathy), <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> decreases mortality and need for liver transplantation. The Modified King's College Criteria  (<a class="graphic graphic_algorithm graphicRef143516" href="/z/d/graphic/143516.html" rel="external">algorithm 1</a>) can help determine prognosis without liver transplantation. (See <a class="local">'Fulminant hepatic failure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of extracorporal removal following high-risk ingestion</strong> – In a patient with a serum <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> concentration ≥900 mcg/mL (5960 micromol/L) and altered mental status or metabolic acidosis, we suggest hemodialysis in addition to <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Hemodialysis can clear acetaminophen and toxic metabolites from serum and can also correct a metabolic acidosis. (See <a class="local">'Role of extracorporeal removal'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exploratory ingestions in young children </strong>– These<strong> </strong>exposures typically involve small amounts of <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> in an otherwise asymptomatic child and rarely result in liver injury. They are treated similarly to acute ingestions in adults. (See <a class="local">'Exploratory ingestions in young children'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Dart RC, Mullins ME, Matoushek T, et al. Management of Acetaminophen Poisoning in the US and Canada: A Consensus Statement. JAMA Netw Open 2023; 6:e2327739.</a></li><li><a class="nounderline abstract_t">Smilkstein MJ, Bronstein AC, Linden C, et al. Acetaminophen overdose: a 48-hour intravenous N-acetylcysteine treatment protocol. Ann Emerg Med 1991; 20:1058.</a></li><li><a class="nounderline abstract_t">Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N Engl J Med 1988; 319:1557.</a></li><li><a class="nounderline abstract_t">Prescott LF. Treatment of severe acetaminophen poisoning with intravenous acetylcysteine. Arch Intern Med 1981; 141:386.</a></li><li><a class="nounderline abstract_t">Chiew AL, Isbister GK, Kirby KA, et al. Massive paracetamol overdose: an observational study of the effect of activated charcoal and increased acetylcysteine dose (ATOM-2). Clin Toxicol (Phila) 2017; 55:1055.</a></li><li><a class="nounderline abstract_t">Chiew AL, Gluud C, Brok J, Buckley NA. Interventions for paracetamol (acetaminophen) overdose. Cochrane Database Syst Rev 2018; 2:CD003328.</a></li><li><a class="nounderline abstract_t">Underhill TJ, Greene MK, Dove AF. A comparison of the efficacy of gastric lavage, ipecacuanha and activated charcoal in the emergency management of paracetamol overdose. Arch Emerg Med 1990; 7:148.</a></li><li><a class="nounderline abstract_t">Spiller HA, Krenzelok EP, Grande GA, et al. A prospective evaluation of the effect of activated charcoal before oral N-acetylcysteine in acetaminophen overdose. Ann Emerg Med 1994; 23:519.</a></li><li><a class="nounderline abstract_t">Buckley NA, Whyte IM, O'Connell DL, Dawson AH. Activated charcoal reduces the need for N-acetylcysteine treatment after acetaminophen (paracetamol) overdose. J Toxicol Clin Toxicol 1999; 37:753.</a></li><li><a class="nounderline abstract_t">Bond GR, Requa RK, Krenzelok EP, et al. Influence of time until emesis on the efficacy of decontamination using acetaminophen as a marker in a pediatric population. Ann Emerg Med 1993; 22:1403.</a></li><li><a class="nounderline abstract_t">Position paper: Ipecac syrup. J Toxicol Clin Toxicol 2004; 42:133.</a></li><li><a class="nounderline abstract_t">Grierson R, Green R, Sitar DS, Tenenbein M. Gastric lavage for liquid poisons. Ann Emerg Med 2000; 35:435.</a></li><li><a class="nounderline abstract_t">Vale JA, Kulig K, American Academy of Clinical Toxicology, European Association of Poisons Centres and Clinical Toxicologists. Position paper: gastric lavage. J Toxicol Clin Toxicol 2004; 42:933.</a></li><li><a class="nounderline abstract_t">Spiller HA, Winter ML, Klein-Schwartz W, Bangh SA. Efficacy of activated charcoal administered more than four hours after acetaminophen overdose. J Emerg Med 2006; 30:1.</a></li><li><a class="nounderline abstract_t">Kerr F, Dawson A, Whyte IM, et al. The Australasian Clinical Toxicology Investigators Collaboration randomized trial of different loading infusion rates of N-acetylcysteine. Ann Emerg Med 2005; 45:402.</a></li><li><a class="nounderline abstract_t">Heard KJ. Acetylcysteine for acetaminophen poisoning. N Engl J Med 2008; 359:285.</a></li><li><a class="nounderline abstract_t">Yoon E, Babar A, Choudhary M, et al. Acetaminophen-Induced Hepatotoxicity: a Comprehensive Update. J Clin Transl Hepatol 2016; 4:131.</a></li><li><a class="nounderline abstract_t">Keays R, Harrison PM, Wendon JA, et al. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. BMJ 1991; 303:1026.</a></li><li><a class="nounderline abstract_t">Bailey B, Amre DK, Gaudreault P. Fulminant hepatic failure secondary to acetaminophen poisoning: a systematic review and meta-analysis of prognostic criteria determining the need for liver transplantation. Crit Care Med 2003; 31:299.</a></li><li><a class="nounderline abstract_t">Fontana RJ. Acute liver failure including acetaminophen overdose. Med Clin North Am 2008; 92:761.</a></li><li><a class="nounderline abstract_t">Bernal W, Donaldson N, Wyncoll D, Wendon J. Blood lactate as an early predictor of outcome in paracetamol-induced acute liver failure: a cohort study. Lancet 2002; 359:558.</a></li><li><a class="nounderline abstract_t">O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97:439.</a></li><li><a class="nounderline abstract_t">Dart RC, Rumack BH. Intravenous acetaminophen in the United States: iatrogenic dosing errors. Pediatrics 2012; 129:349.</a></li><li><a class="nounderline abstract_t">Gray T, Hoffman RS, Bateman DN. Intravenous paracetamol--an international perspective of toxicity. Clin Toxicol (Phila) 2011; 49:150.</a></li><li><a class="nounderline abstract_t">Beringer RM, Thompson JP, Parry S, Stoddart PA. Intravenous paracetamol overdose: two case reports and a change to national treatment guidelines. Arch Dis Child 2011; 96:307.</a></li><li><a class="nounderline abstract_t">Gosselin S, Juurlink DN, Kielstein JT, et al. Extracorporeal treatment for acetaminophen poisoning: recommendations from the EXTRIP workgroup. Clin Toxicol (Phila) 2014; 52:856.</a></li><li><a class="nounderline abstract_t">Wu ML, Tsai WJ, Deng JF, Yang CC. Hemodialysis as adjunctive therapy for severe acetaminophen poisoning: a case report. Zhonghua Yi Xue Za Zhi (Taipei) 1999; 62:907.</a></li><li><a class="nounderline abstract_t">Marbury TC, Wang LH, Lee CS. Hemodialysis of acetaminophen in uremic patients. Int J Artif Organs 1980; 3:263.</a></li><li><a class="nounderline abstract_t">Green JL, Heard KJ, Reynolds KM, Albert D. Oral and Intravenous Acetylcysteine for Treatment of Acetaminophen Toxicity: A Systematic Review and Meta-analysis. West J Emerg Med 2013; 14:218.</a></li><li><a class="nounderline abstract_t">Schwarz E, Cohn B. Is intravenous acetylcysteine more effective than oral administration for the prevention of hepatotoxicity in acetaminophen overdose? Ann Emerg Med 2014; 63:79.</a></li><li><a class="nounderline abstract_t">Yarema M, Chopra P, Sivilotti MLA, et al. Anaphylactoid Reactions to Intravenous N-Acetylcysteine during Treatment for Acetaminophen Poisoning. J Med Toxicol 2018; 14:120.</a></li><li><a class="nounderline abstract_t">Prescott LF, Park J, Ballantyne A, et al. Treatment of paracetamol (acetaminophen) poisoning with N-acetylcysteine. Lancet 1977; 2:432.</a></li><li><a class="nounderline abstract_t">Wong A, Graudins A. Simplification of the standard three-bag intravenous acetylcysteine regimen for paracetamol poisoning results in a lower incidence of adverse drug reactions. Clin Toxicol (Phila) 2016; 54:115.</a></li><li><a class="nounderline abstract_t">Bateman DN, Dear JW, Thanacoody HK, et al. Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. Lancet 2014; 383:697.</a></li><li><a class="nounderline abstract_t">Schmidt LE, Rasmussen DN, Petersen TS, et al. Fewer adverse effects associated with a modified two-bag intravenous acetylcysteine protocol compared to traditional three-bag regimen in paracetamol overdose. Clin Toxicol (Phila) 2018; 56:1128.</a></li><li><a class="nounderline abstract_t">McNulty R, Lim JME, Chandru P, Gunja N. Fewer adverse effects with a modified two-bag acetylcysteine protocol in paracetamol overdose. Clin Toxicol (Phila) 2018; 56:618.</a></li><li><a class="nounderline abstract_t">O'Callaghan C, Graudins A, Wong A. A two-bag acetylcysteine regimen is associated with shorter delays and interruptions in the treatment of paracetamol overdose. Clin Toxicol (Phila) 2022; 60:319.</a></li><li><a class="nounderline abstract_t">Isbister GK, Downes MA, Mcnamara K, et al. A prospective observational study of a novel 2-phase infusion protocol for the administration of acetylcysteine in paracetamol poisoning. Clin Toxicol (Phila) 2016; 54:120.</a></li><li><a class="nounderline abstract_t">Williamson K, Wahl MS, Mycyk MB. Direct comparison of 20-hour IV, 36-hour oral, and 72-hour oral acetylcysteine for treatment of acute acetaminophen poisoning. Am J Ther 2013; 20:37.</a></li><li><a class="nounderline abstract_t">Betten DP, Burner EE, Thomas SC, et al. A retrospective evaluation of shortened-duration oral N-acetylcysteine for the treatment of acetaminophen poisoning. J Med Toxicol 2009; 5:183.</a></li><li><a class="nounderline abstract_t">Woo OF, Mueller PD, Olson KR, et al. Shorter duration of oral N -Acetylcysteine therapy for acute acetaminophen overdose. Ann Emerg Med 2000; 35:363.</a></li><li class="breakAll">Cumberland Pharmaceuticals. [Physician Letter - Acetadote® (acetylcysteine) Injection: Dosing in Patients Weighing over 100 kg]. 9.28.06. Available from: Cumberland Pharmaceuticals <a class="__cf_email__" data-cfemail="cfa6a1a9a08facbaa2adaabda3aea1abbfa7aebda2aee1aca0a2" href="/cdn-cgi/l/email-protection">[email protected]</a>. </li><li><a class="nounderline abstract_t">Varney SM, Buchanan JA, Kokko J, Heard K. Acetylcysteine for acetaminophen overdose in patients who weigh &gt;100 kg. Am J Ther 2014; 21:159.</a></li><li><a class="nounderline abstract_t">Rumack BH, Bateman DN. Acetaminophen and acetylcysteine dose and duration: past, present and future. Clin Toxicol (Phila) 2012; 50:91.</a></li><li><a class="nounderline abstract_t">Schwartz EA, Hayes BD, Sarmiento KF. Development of hepatic failure despite use of intravenous acetylcysteine after a massive ingestion of acetaminophen and diphenhydramine. Ann Emerg Med 2009; 54:421.</a></li><li><a class="nounderline abstract_t">Wang GS, Monte A, Bagdure D, Heard K. Hepatic failure despite early acetylcysteine following large acetaminophen-diphenhydramine overdose. Pediatrics 2011; 127:e1077.</a></li><li><a class="nounderline abstract_t">Doyon S, Klein-Schwartz W. Hepatotoxicity despite early administration of intravenous N-acetylcysteine for acute acetaminophen overdose. Acad Emerg Med 2009; 16:34.</a></li><li><a class="nounderline abstract_t">Cairney DG, Beckwith HK, Al-Hourani K, et al. Plasma paracetamol concentration at hospital presentation has a dose-dependent relationship with liver injury despite prompt treatment with intravenous acetylcysteine. Clin Toxicol (Phila) 2016; 54:405.</a></li><li><a class="nounderline abstract_t">Woodhead JL, Howell BA, Yang Y, et al. An analysis of N-acetylcysteine treatment for acetaminophen overdose using a systems model of drug-induced liver injury. J Pharmacol Exp Ther 2012; 342:529.</a></li><li><a class="nounderline abstract_t">Sivilotti ML, Juurlink DN, Garland JS, et al. Antidote removal during haemodialysis for massive acetaminophen overdose. Clin Toxicol (Phila) 2013; 51:855.</a></li><li><a class="nounderline abstract_t">Hernandez SH, Howland M, Schiano TD, Hoffman RS. The pharmacokinetics and extracorporeal removal of N-acetylcysteine during renal replacement therapies. Clin Toxicol (Phila) 2015; 53:941.</a></li><li><a class="nounderline abstract_t">Hayes BD, Klein-Schwartz W, Doyon S. Frequency of medication errors with intravenous acetylcysteine for acetaminophen overdose. Ann Pharmacother 2008; 42:766.</a></li><li><a class="nounderline abstract_t">Dawson AH, Henry DA, McEwen J. Adverse reactions to N-acetylcysteine during treatment for paracetamol poisoning. Med J Aust 1989; 150:329.</a></li><li><a class="nounderline abstract_t">Bailey B, McGuigan MA. Management of anaphylactoid reactions to intravenous N-acetylcysteine. Ann Emerg Med 1998; 31:710.</a></li><li><a class="nounderline abstract_t">Yip L, Dart RC. A 20-hour treatment for acute acetaminophen overdose. N Engl J Med 2003; 348:2471.</a></li><li><a class="nounderline abstract_t">Clark RF, Chen R, Williams SR, et al. The use of ondansetron in the treatment of nausea and vomiting associated with acetaminophen poisoning. J Toxicol Clin Toxicol 1996; 34:163.</a></li><li><a class="nounderline abstract_t">Whyte IM, Buckley NA, Reith DM, et al. Acetaminophen causes an increased International Normalized Ratio by reducing functional factor VII. Ther Drug Monit 2000; 22:742.</a></li><li><a class="nounderline abstract_t">Smith SW, Howland MA, Hoffman RS, Nelson LS. Acetaminophen overdose with altered acetaminophen pharmacokinetics and hepatotoxicity associated with premature cessation of intravenous N-acetylcysteine therapy. Ann Pharmacother 2008; 42:1333.</a></li><li><a class="nounderline abstract_t">Dart RC, Rumack BH. Patient-tailored acetylcysteine administration. Ann Emerg Med 2007; 50:280.</a></li><li><a class="nounderline abstract_t">Betten DP, Cantrell FL, Thomas SC, et al. A prospective evaluation of shortened course oral N-acetylcysteine for the treatment of acute acetaminophen poisoning. Ann Emerg Med 2007; 50:272.</a></li><li><a class="nounderline abstract_t">Daly FF, Fountain JS, Murray L, et al. Guidelines for the management of paracetamol poisoning in Australia and New Zealand--explanation and elaboration. A consensus statement from clinical toxicologists consulting to the Australasian poisons information centres. Med J Aust 2008; 188:296.</a></li><li><a class="nounderline abstract_t">Wallace CI, Dargan PI, Jones AL. Paracetamol overdose: an evidence based flowchart to guide management. Emerg Med J 2002; 19:202.</a></li><li><a class="nounderline abstract_t">Pettie JM, Caparrotta TM, Hunter RW, et al. Safety and Efficacy of the SNAP 12-hour Acetylcysteine Regimen for the Treatment of Paracetamol Overdose. EClinicalMedicine 2019; 11:11.</a></li><li><a class="nounderline abstract_t">Corcoran GB, Mitchell JR, Vaishnav YN, Horning EC. Evidence that acetaminophen and N-hydroxyacetaminophen form a common arylating intermediate, N-acetyl-p-benzoquinoneimine. Mol Pharmacol 1980; 18:536.</a></li><li><a class="nounderline abstract_t">Hamlyn AN, Douglas AP, James O. The spectrum of paracetamol (acetaminophen) overdose: clinical and epidemiological studies. Postgrad Med J 1978; 54:400.</a></li><li><a class="nounderline abstract_t">Rumack BH, Peterson RC, Koch GG, Amara IA. Acetaminophen overdose. 662 cases with evaluation of oral acetylcysteine treatment. Arch Intern Med 1981; 141:380.</a></li><li><a class="nounderline abstract_t">Heard K, Rumack BH, Green JL, et al. A single-arm clinical trial of a 48-hour intravenous N-acetylcysteine protocol for treatment of acetaminophen poisoning. Clin Toxicol (Phila) 2014; 52:512.</a></li><li><a class="nounderline abstract_t">Harrison PM, Keays R, Bray GP, et al. Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet 1990; 335:1572.</a></li><li><a class="nounderline abstract_t">Harrison PM, Wendon JA, Gimson AE, et al. Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med 1991; 324:1852.</a></li><li><a class="nounderline abstract_t">Prescott LF, Illingworth RN, Critchley JA, et al. Intravenous N-acetylcystine: the treatment of choice for paracetamol poisoning. Br Med J 1979; 2:1097.</a></li><li><a class="nounderline abstract_t">Antoine DJ, Dear JW, Lewis PS, et al. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology 2013; 58:777.</a></li><li><a class="nounderline abstract_t">Wong A, Sivilotti ML, Dargan PI, et al. External validation of the paracetamol-aminotransferase multiplication product to predict hepatotoxicity from paracetamol overdose. Clin Toxicol (Phila) 2015; 53:807.</a></li><li><a class="nounderline abstract_t">Wong A, Sivilotti MLA, Graudins A. Accuracy of the paracetamol-aminotransferase multiplication product to predict hepatotoxicity in modified-release paracetamol overdose. Clin Toxicol (Phila) 2017; 55:346.</a></li><li><a class="nounderline abstract_t">Wong A, Graudins A. Risk prediction of hepatotoxicity in paracetamol poisoning. Clin Toxicol (Phila) 2017; 55:879.</a></li><li><a class="nounderline abstract_t">Küçükardali Y, Cinan U, Acar HV, et al. Comparison of the therapeutic efficacy of 4-methylpyrazole and N-acetylcysteine on acetaminophen (paracetamol) hepatotoxicity in rats. Curr Med Res Opin 2002; 18:78.</a></li><li><a class="nounderline abstract_t">Akakpo JY, Ramachandran A, Kandel SE, et al. 4-Methylpyrazole protects against acetaminophen hepatotoxicity in mice and in primary human hepatocytes. Hum Exp Toxicol 2018; 37:1310.</a></li><li><a class="nounderline abstract_t">Brennan RJ, Mankes RF, Lefevre R, et al. 4-Methylpyrazole blocks acetaminophen hepatotoxicity in the rat. Ann Emerg Med 1994; 23:487.</a></li><li><a class="nounderline abstract_t">Akakpo JY, Ramachandran A, Duan L, et al. Delayed Treatment With 4-Methylpyrazole Protects Against Acetaminophen Hepatotoxicity in Mice by Inhibition of c-Jun n-Terminal Kinase. Toxicol Sci 2019; 170:57.</a></li><li><a class="nounderline abstract_t">Kang AM, Padilla-Jones A, Fisher ES, et al. The Effect of 4-Methylpyrazole on Oxidative Metabolism of Acetaminophen in Human Volunteers. J Med Toxicol 2020; 16:169.</a></li><li><a class="nounderline abstract_t">Shah KR, Beuhler MC. Fomepizole as an Adjunctive Treatment in Severe Acetaminophen Toxicity. Am J Emerg Med 2020; 38:410.e5.</a></li><li><a class="nounderline abstract_t">Shah KR, Fox C, Geib AJ, et al. Fomepizole as an adjunctive treatment in severe acetaminophen ingestions: a case series. Clin Toxicol (Phila) 2021; 59:71.</a></li><li><a class="nounderline abstract_t">Link SL, Rampon G, Osmon S, et al. Fomepizole as an adjunct in acetylcysteine treated acetaminophen overdose patients: a case series. Clin Toxicol (Phila) 2022; 60:472.</a></li><li><a class="nounderline abstract_t">Brent J. Fomepizole for ethylene glycol and methanol poisoning. N Engl J Med 2009; 360:2216.</a></li><li><a class="nounderline abstract_t">Riggs BS, Bronstein AC, Kulig K, et al. Acute acetaminophen overdose during pregnancy. Obstet Gynecol 1989; 74:247.</a></li><li><a class="nounderline abstract_t">McElhatton PR, Sullivan FM, Volans GN. Paracetamol overdose in pregnancy analysis of the outcomes of 300 cases referred to the Teratology Information Service. Reprod Toxicol 1997; 11:85.</a></li><li><a class="nounderline abstract_t">Horowitz RS, Dart RC, Jarvie DR, et al. Placental transfer of N-acetylcysteine following human maternal acetaminophen toxicity. J Toxicol Clin Toxicol 1997; 35:447.</a></li><li><a class="nounderline abstract_t">Roberts I, Robinson MJ, Mughal MZ, et al. Paracetamol metabolites in the neonate following maternal overdose. Br J Clin Pharmacol 1984; 18:201.</a></li><li><a class="nounderline abstract_t">Sancewicz-Pach K, Chmiest W, Lichota E. Suicidal paracetamol poisoning of a pregnant woman just before a delivery. Przegl Lek 1999; 56:459.</a></li><li><a class="nounderline abstract_t">Haibach H, Akhter JE, Muscato MS, et al. Acetaminophen overdose with fetal demise. Am J Clin Pathol 1984; 82:240.</a></li><li><a class="nounderline abstract_t">Stokes IM. Paracetamol overdose in the second trimester of pregnancy. Case report. Br J Obstet Gynaecol 1984; 91:286.</a></li><li><a class="nounderline abstract_t">Rosevear SK, Hope PL. Favourable neonatal outcome following maternal paracetamol overdose and severe fetal distress. Case report. Br J Obstet Gynaecol 1989; 96:491.</a></li><li><a class="nounderline abstract_t">Lederman S, Fysh WJ, Tredger M, Gamsu HR. Neonatal paracetamol poisoning: treatment by exchange transfusion. Arch Dis Child 1983; 58:631.</a></li><li><a class="nounderline abstract_t">McElhatton PR, Sullivan FM, Volans GN, Fitzpatrick R. Paracetamol poisoning in pregnancy: an analysis of the outcomes of cases referred to the Teratology Information Service of the National Poisons Information Service. Hum Exp Toxicol 1990; 9:147.</a></li><li><a class="nounderline abstract_t">Daly FF, O'Malley GF, Heard K, et al. Prospective evaluation of repeated supratherapeutic acetaminophen (paracetamol) ingestion. Ann Emerg Med 2004; 44:393.</a></li><li><a class="nounderline abstract_t">Wang PH, Yang MJ, Lee WL, et al. Acetaminophen poisoning in late pregnancy. A case report. J Reprod Med 1997; 42:367.</a></li><li><a class="nounderline abstract_t">Sztajnkrycer MJ, Bond GR. Chronic acetaminophen overdosing in children: risk assessment and management. Curr Opin Pediatr 2001; 13:177.</a></li><li><a class="nounderline abstract_t">Rivera-Penera T, Gugig R, Davis J, et al. Outcome of acetaminophen overdose in pediatric patients and factors contributing to hepatotoxicity. J Pediatr 1997; 130:300.</a></li><li><a class="nounderline abstract_t">Heubi JE, Barbacci MB, Zimmerman HJ. Therapeutic misadventures with acetaminophen: hepatoxicity after multiple doses in children. J Pediatr 1998; 132:22.</a></li><li><a class="nounderline abstract_t">Anker AL, Smilkstein MJ. Acetaminophen. Concepts and controversies. Emerg Med Clin North Am 1994; 12:335.</a></li><li><a class="nounderline abstract_t">Mahadevan SB, McKiernan PJ, Davies P, Kelly DA. Paracetamol induced hepatotoxicity. Arch Dis Child 2006; 91:598.</a></li><li><a class="nounderline abstract_t">Kearns GL, Leeder JS, Wasserman GS. Acetaminophen intoxication during treatment: what you don't know can hurt you. Clin Pediatr (Phila) 2000; 39:133.</a></li><li><a class="nounderline abstract_t">Divoll M, Greenblatt DJ, Ameer B, Abernethy DR. Effect of food on acetaminophen absorption in young and elderly subjects. J Clin Pharmacol 1982; 22:571.</a></li><li><a class="nounderline abstract_t">Heubi JE, Bien JP. Acetaminophen use in children: more is not better. J Pediatr 1997; 130:175.</a></li><li><a class="nounderline abstract_t">Birmingham PK, Tobin MJ, Henthorn TK, et al. Twenty-four-hour pharmacokinetics of rectal acetaminophen in children: an old drug with new recommendations. Anesthesiology 1997; 87:244.</a></li><li><a class="nounderline abstract_t">van Lingen RA, Deinum HT, Quak CM, et al. Multiple-dose pharmacokinetics of rectally administered acetaminophen in term infants. Clin Pharmacol Ther 1999; 66:509.</a></li><li><a class="nounderline abstract_t">Cullen S, Kenny D, Ward OC, Sabra K. Paracetamol suppositories: a comparative study. Arch Dis Child 1989; 64:1504.</a></li><li><a class="nounderline abstract_t">Henretig FM, Selbst SM, Forrest C, et al. Repeated acetaminophen overdosing. Causing hepatotoxicity in children. Clinical reports and literature review. Clin Pediatr (Phila) 1989; 28:525.</a></li></ol></div><div id="topicVersionRevision">Topic 318 Version 50.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37552484" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Management of Acetaminophen Poisoning in the US and Canada: A Consensus Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1928874" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Acetaminophen overdose: a 48-hour intravenous N-acetylcysteine treatment protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3059186" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7469630" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Treatment of severe acetaminophen poisoning with intravenous acetylcysteine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28644687" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Massive paracetamol overdose: an observational study of the effect of activated charcoal and increased acetylcysteine dose (ATOM-2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29473717" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Interventions for paracetamol (acetaminophen) overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1983801" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A comparison of the efficacy of gastric lavage, ipecacuanha and activated charcoal in the emergency management of paracetamol overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8135427" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A prospective evaluation of the effect of activated charcoal before oral N-acetylcysteine in acetaminophen overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10584587" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Activated charcoal reduces the need for N-acetylcysteine treatment after acetaminophen (paracetamol) overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8103306" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Influence of time until emesis on the efficacy of decontamination using acetaminophen as a marker in a pediatric population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15214617" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Position paper: Ipecac syrup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10783405" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Gastric lavage for liquid poisons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15641639" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Position paper: gastric lavage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16434328" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Efficacy of activated charcoal administered more than four hours after acetaminophen overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15795719" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The Australasian Clinical Toxicology Investigators Collaboration randomized trial of different loading infusion rates of N-acetylcysteine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18635433" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Acetylcysteine for acetaminophen poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27350943" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Acetaminophen-Induced Hepatotoxicity: a Comprehensive Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1954453" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12545033" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Fulminant hepatic failure secondary to acetaminophen poisoning: a systematic review and meta-analysis of prognostic criteria determining the need for liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18570942" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Acute liver failure including acetaminophen overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11867109" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Blood lactate as an early predictor of outcome in paracetamol-induced acute liver failure: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2490426" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Early indicators of prognosis in fulminant hepatic failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22271694" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Intravenous acetaminophen in the United States: iatrogenic dosing errors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21443426" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Intravenous paracetamol--an international perspective of toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21127004" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Intravenous paracetamol overdose: two case reports and a change to national treatment guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25133498" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Extracorporeal treatment for acetaminophen poisoning: recommendations from the EXTRIP workgroup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10634007" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Hemodialysis as adjunctive therapy for severe acetaminophen poisoning: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7461859" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Hemodialysis of acetaminophen in uremic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23687539" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Oral and Intravenous Acetylcysteine for Treatment of Acetaminophen Toxicity: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23927960" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Is intravenous acetylcysteine more effective than oral administration for the prevention of hepatotoxicity in acetaminophen overdose?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29423816" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Anaphylactoid Reactions to Intravenous N-Acetylcysteine during Treatment for Acetaminophen Poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/70646" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Treatment of paracetamol (acetaminophen) poisoning with N-acetylcysteine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26594846" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Simplification of the standard three-bag intravenous acetylcysteine regimen for paracetamol poisoning results in a lower incidence of adverse drug reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24290406" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29792347" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Fewer adverse effects associated with a modified two-bag intravenous acetylcysteine protocol compared to traditional three-bag regimen in paracetamol overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29219630" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Fewer adverse effects with a modified two-bag acetylcysteine protocol in paracetamol overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34402711" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A two-bag acetylcysteine regimen is associated with shorter delays and interruptions in the treatment of paracetamol overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26691690" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A prospective observational study of a novel 2-phase infusion protocol for the administration of acetylcysteine in paracetamol poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23299230" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Direct comparison of 20-hour IV, 36-hour oral, and 72-hour oral acetylcysteine for treatment of acute acetaminophen poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19876849" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A retrospective evaluation of shortened-duration oral N-acetylcysteine for the treatment of acetaminophen poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28140232" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Shorter duration of oral N -Acetylcysteine therapy for acute acetaminophen overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28140232" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Shorter duration of oral N -Acetylcysteine therapy for acute acetaminophen overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23011167" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Acetylcysteine for acetaminophen overdose in patients who weigh&gt;100 kg.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22320209" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Acetaminophen and acetylcysteine dose and duration: past, present and future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18986731" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Development of hepatic failure despite use of intravenous acetylcysteine after a massive ingestion of acetaminophen and diphenhydramine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21402629" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Hepatic failure despite early acetylcysteine following large acetaminophen-diphenhydramine overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19007345" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Hepatotoxicity despite early administration of intravenous N-acetylcysteine for acute acetaminophen overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27108714" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Plasma paracetamol concentration at hospital presentation has a dose-dependent relationship with liver injury despite prompt treatment with intravenous acetylcysteine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22593093" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : An analysis of N-acetylcysteine treatment for acetaminophen overdose using a systems model of drug-induced liver injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24134534" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Antidote removal during haemodialysis for massive acetaminophen overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26484583" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The pharmacokinetics and extracorporeal removal of N-acetylcysteine during renal replacement therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18445707" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Frequency of medication errors with intravenous acetylcysteine for acetaminophen overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2716644" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Adverse reactions to N-acetylcysteine during treatment for paracetamol poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9624310" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Management of anaphylactoid reactions to intravenous N-acetylcysteine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12802041" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A 20-hour treatment for acute acetaminophen overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8618249" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The use of ondansetron in the treatment of nausea and vomiting associated with acetaminophen poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11128244" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Acetaminophen causes an increased International Normalized Ratio by reducing functional factor VII.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18628444" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Acetaminophen overdose with altered acetaminophen pharmacokinetics and hepatotoxicity associated with premature cessation of intravenous N-acetylcysteine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17418449" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Patient-tailored acetylcysteine administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17210206" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A prospective evaluation of shortened course oral N-acetylcysteine for the treatment of acute acetaminophen poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18312195" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Guidelines for the management of paracetamol poisoning in Australia and New Zealand--explanation and elaboration. A consensus statement from clinical toxicologists consulting to the Australasian poisons information centres.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11971827" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Paracetamol overdose: an evidence based flowchart to guide management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31317129" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Safety and Efficacy of the SNAP 12-hour Acetylcysteine Regimen for the Treatment of Paracetamol Overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7464816" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Evidence that acetaminophen and N-hydroxyacetaminophen form a common arylating intermediate, N-acetyl-p-benzoquinoneimine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/683908" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The spectrum of paracetamol (acetaminophen) overdose: clinical and epidemiological studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7469629" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Acetaminophen overdose. 662 cases with evaluation of oral acetylcysteine treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24708414" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A single-arm clinical trial of a 48-hour intravenous N-acetylcysteine protocol for treatment of acetaminophen poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1972496" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1904133" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/519312" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Intravenous N-acetylcystine: the treatment of choice for paracetamol poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23390034" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26175095" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : External validation of the paracetamol-aminotransferase multiplication product to predict hepatotoxicity from paracetamol overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28421844" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Accuracy of the paracetamol-aminotransferase multiplication product to predict hepatotoxicity in modified-release paracetamol overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28447858" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Risk prediction of hepatotoxicity in paracetamol poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12017214" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Comparison of the therapeutic efficacy of 4-methylpyrazole and N-acetylcysteine on acetaminophen (paracetamol) hepatotoxicity in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29739258" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : 4-Methylpyrazole protects against acetaminophen hepatotoxicity in mice and in primary human hepatocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8135423" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : 4-Methylpyrazole blocks acetaminophen hepatotoxicity in the rat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30903181" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Delayed Treatment With 4-Methylpyrazole Protects Against Acetaminophen Hepatotoxicity in Mice by Inhibition of c-Jun n-Terminal Kinase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31768936" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The Effect of 4-Methylpyrazole on Oxidative Metabolism of Acetaminophen in Human Volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31785979" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Fomepizole as an Adjunctive Treatment in Severe Acetaminophen Toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32538692" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Fomepizole as an adjunctive treatment in severe acetaminophen ingestions: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34709101" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Fomepizole as an adjunct in acetylcysteine treated acetaminophen overdose patients: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19458366" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Fomepizole for ethylene glycol and methanol poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2748061" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Acute acetaminophen overdose during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9138637" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Paracetamol overdose in pregnancy analysis of the outcomes of 300 cases referred to the Teratology Information Service.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9279300" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Placental transfer of N-acetylcysteine following human maternal acetaminophen toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6487458" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Paracetamol metabolites in the neonate following maternal overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10465999" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Suicidal paracetamol poisoning of a pregnant woman just before a delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6465090" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Acetaminophen overdose with fetal demise.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6704353" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Paracetamol overdose in the second trimester of pregnancy. Case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2751965" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Favourable neonatal outcome following maternal paracetamol overdose and severe fetal distress. Case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6614980" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Neonatal paracetamol poisoning: treatment by exchange transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2198067" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Paracetamol poisoning in pregnancy: an analysis of the outcomes of cases referred to the Teratology Information Service of the National Poisons Information Service.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15459622" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Prospective evaluation of repeated supratherapeutic acetaminophen (paracetamol) ingestion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9219126" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Acetaminophen poisoning in late pregnancy. A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11317062" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Chronic acetaminophen overdosing in children: risk assessment and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9042136" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Outcome of acetaminophen overdose in pediatric patients and factors contributing to hepatotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9469995" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Therapeutic misadventures with acetaminophen: hepatoxicity after multiple doses in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8187687" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Acetaminophen. Concepts and controversies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16547087" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Paracetamol induced hepatotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10752006" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Acetaminophen intoxication during treatment: what you don't know can hurt you.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7161411" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Effect of food on acetaminophen absorption in young and elderly subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9042116" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Acetaminophen use in children: more is not better.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9286887" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Twenty-four-hour pharmacokinetics of rectal acetaminophen in children: an old drug with new recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10579478" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Multiple-dose pharmacokinetics of rectally administered acetaminophen in term infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2817936" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Paracetamol suppositories: a comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2680215" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Repeated acetaminophen overdosing. Causing hepatotoxicity in children. Clinical reports and literature review.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
